[{"trial_id":6533,"title":"Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study","summary":"<b>Conditions</b>:    Systemic Sclerosis;   Multisystem Disorder<br /><b>Intervention</b>:    Other: MRI<br /><b>Sponsors</b>:    Tsinghua University;   Peking Union Medical College Hospital<br /><b>Recruiting</b>","published_date":"2022-03-28T16:00:00Z","discovery_date":"2022-03-28T11:41:38.700399Z","link":"https://clinicaltrials.gov/ct2/show/NCT05297474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":6530,"title":"Gait Analysis in Multiple Sclerosis Patients","summary":"<b>Conditions</b>:    Multiple Sclerosis;   3D Gait Analysis;   Vestibular Rehabilitation<br /><b>Interventions</b>:    Other: Vestibular exercises;   Other: Standard neurorehabilitation exercises<br /><b>Sponsors</b>:    Istanbul Kültür University;   Istanbul University-Cerrahpasa<br /><b>Not yet recruiting</b>","published_date":"2022-03-28T16:00:00Z","discovery_date":"2022-03-28T11:41:38.697822Z","link":"https://clinicaltrials.gov/ct2/show/NCT05299151?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":6526,"title":"Drug Repurposing for Improving the Therapeutic Outcome in Multiple Sclerosis Patients","summary":"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet;   Drug: Interferon beta-1a<br /><b>Sponsor</b>:    German University in Cairo<br /><b>Not yet recruiting</b>","published_date":"2022-03-28T16:00:00Z","discovery_date":"2022-03-28T11:41:38.693998Z","link":"https://clinicaltrials.gov/ct2/show/NCT05298670?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":5579,"title":"B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis","summary":"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Ocrelizumab<br /><b>Sponsor</b>:    VU University Medical Center<br /><b>Not yet recruiting</b>","published_date":"2022-03-25T16:00:00Z","discovery_date":"2022-03-25T11:41:38.145928Z","link":"https://clinicaltrials.gov/ct2/show/NCT05296161?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":5005,"title":"An Assistive Powered Wheelchair: Stage 2 Trial","summary":"<b>Conditions</b>:    Multiple Sclerosis;   Stroke;   Cystic Fibrosis;   Motor Neurone Disease;   Craniocerebral Trauma;   Guillain-Barre Syndrome<br /><b>Intervention</b>:    Device: Powered Wheelchair Obstacle Alerting System<br /><b>Sponsors</b>:    East Kent Hospitals University NHS Foundation Trust;   University of Kent;   Sussex Community NHS Foundation Trust;   KU Leuven;   l'Institut supérieur de l'électronique et du numérique (ISEN) Lille<br /><b>Completed</b>","published_date":"2022-03-23T16:00:00Z","discovery_date":"2022-03-23T14:40:22.014022Z","link":"https://clinicaltrials.gov/ct2/show/NCT05292690?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":4667,"title":"Cellular microRNA Signatures in Multiple Sclerosis","summary":"<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Genetic: 50 ml blodd sampling<br /><b>Sponsors</b>:    Institut Pasteur;   Höpital La Pitié-Salpêtrière<br /><b>Not yet recruiting</b>","published_date":"2022-03-22T16:00:00Z","discovery_date":"2022-03-22T12:37:56.690857Z","link":"https://clinicaltrials.gov/ct2/show/NCT05290688?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":3318,"title":"Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients","summary":"<b>Conditions</b>:    Multiple Sclerosis;   Autoimmune Blistering Disease;   B-Cell Deficiency<br /><b>Intervention</b>:    Biological: COVID19 vaccine<br /><b>Sponsors</b>:    Yale University;   National Institute of Allergy and Infectious Diseases (NIAID);   Robert Leet and Clara Guthrie Patterson Trust<br /><b>Active, not recruiting</b>","published_date":"2022-03-18T16:00:00Z","discovery_date":"2022-03-18T12:44:44.032425Z","link":"https://clinicaltrials.gov/ct2/show/NCT05286242?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":3310,"title":"Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study","summary":"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatumumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Not yet recruiting</b>","published_date":"2022-03-18T16:00:00Z","discovery_date":"2022-03-18T12:44:44.026375Z","link":"https://clinicaltrials.gov/ct2/show/NCT05285904?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":3308,"title":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","summary":"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Ocrelizumab;   Drug: Placebo for Ocrelizumab<br /><b>Sponsors</b>:    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence (ACE)<br /><b>Not yet recruiting</b>","published_date":"2022-03-18T16:00:00Z","discovery_date":"2022-03-18T12:44:43.303079Z","link":"https://clinicaltrials.gov/ct2/show/NCT05285891?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":2987,"title":"Famciclovir in Multiple Sclerosis","summary":"<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Famciclovir<br /><b>Sponsor</b>:    Queen Mary University of London<br /><b>Recruiting</b>","published_date":"2022-03-17T16:00:00Z","discovery_date":"2022-03-17T12:44:43.883950Z","link":"https://clinicaltrials.gov/ct2/show/NCT05283551?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":2434,"title":"A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers","summary":"<b>Condition</b>:    Amyotrophic Lateral Sclerosis<br /><b>Interventions</b>:    Drug: prosetin;   Drug: placebo<br /><b>Sponsors</b>:    ProJenX;   Worldwide Clinical Trials<br /><b>Recruiting</b>","published_date":"2022-03-15T16:00:00Z","discovery_date":"2022-03-15T19:19:40.664680Z","link":"https://clinicaltrials.gov/ct2/show/NCT05279755?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":2049,"title":"Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis","summary":"<b>Conditions</b>:    Clinically Isolated Syndrome;   Relapsing Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Device: Eye-tracking<br /><b>Sponsors</b>:    McGill University;   Innodem Neurosciences<br /><b>Not yet recruiting</b>","published_date":"2022-03-14T16:00:00Z","discovery_date":"2022-03-14T13:19:41.179332Z","link":"https://clinicaltrials.gov/ct2/show/NCT05277740?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":1286,"title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)","summary":null,"published_date":null,"discovery_date":"2022-03-12T06:20:41.569236Z","link":"https://www.novartis.com//clinicaltrials/study/nct04940065","source":"Novartis","relevant":null},{"trial_id":1214,"title":"","summary":null,"published_date":null,"discovery_date":"2022-03-12T01:20:39.024812Z","link":"https://www.novartis.com/","source":"Novartis","relevant":null},{"trial_id":1175,"title":"A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration","summary":null,"published_date":null,"discovery_date":"2022-03-11T20:20:41.491487Z","link":"https://www.novartis.com//clinicaltrials/study/nct04679935","source":"Novartis","relevant":null},{"trial_id":1150,"title":"Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer&#39;s Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory ...","summary":null,"published_date":null,"discovery_date":"2022-03-11T20:20:41.430654Z","link":"https://www.novartis.com//clinicaltrials/study/nct04795466","source":"Novartis","relevant":null},{"trial_id":1088,"title":"Neuromodulation in MS Using Translingual Stimulation","summary":"<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Combination Product: PT plus translingual stimulation device;   Combination Product: PT plus translingual stimulation control device<br /><b>Sponsors</b>:    University of Saskatchewan;   Memorial University of Newfoundland<br /><b>Enrolling by invitation</b>","published_date":"2022-03-11T17:00:00Z","discovery_date":"2022-03-11T14:47:23.013971Z","link":"https://clinicaltrials.gov/ct2/show/NCT05275049?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":1074,"title":"Pronesimod no tratamento de Esclerose Múltipla Recidivante","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:33.550145Z","link":"https://www.cuf.pt/cuf-academic-center/ensaios-clinicos/pronesimod-no-tratamento-de-esclerose-multipla-recidivante","source":"CUF","relevant":null},{"trial_id":1070,"title":"An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.347794Z","link":"https://www.novartis.com//clinicaltrials/study/nct04868968","source":"Novartis","relevant":null},{"trial_id":1066,"title":"A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.340166Z","link":"https://www.novartis.com//clinicaltrials/study/nct04946318","source":"Novartis","relevant":null},{"trial_id":1062,"title":"Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced&#x2F;Recurrent Non-small Cell Lung Cancer)","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.331596Z","link":"https://www.novartis.com//clinicaltrials/study/nct04575025","source":"Novartis","relevant":null},{"trial_id":1058,"title":"A One-Year, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.316439Z","link":"https://www.novartis.com//clinicaltrials/study/nct04058067","source":"Novartis","relevant":null},{"trial_id":1054,"title":"A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.307013Z","link":"https://www.novartis.com//clinicaltrials/study/nct04812548","source":"Novartis","relevant":null},{"trial_id":1050,"title":"A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.300229Z","link":"https://www.novartis.com//clinicaltrials/study/nct05114746","source":"Novartis","relevant":null},{"trial_id":1049,"title":"More locations","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.295763Z","link":"https://www.novartis.com/","source":"Novartis","relevant":null},{"trial_id":1046,"title":"A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.290363Z","link":"https://www.novartis.com//clinicaltrials/study/nct04926818","source":"Novartis","relevant":null},{"trial_id":1045,"title":"A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD)","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.282894Z","link":"https://www.novartis.com//clinicaltrials/study/nct04632056","source":"Novartis","relevant":null},{"trial_id":1038,"title":"Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:24.269299Z","link":"https://www.novartis.com//clinicaltrials/study/nct04781881","source":"Novartis","relevant":null},{"trial_id":1034,"title":"A Randomized, Open-label, Multi-center, Phase II Study of Asciminib Versus Best Available Therapy in Chinese Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors","summary":null,"published_date":null,"discovery_date":"2022-03-11T11:30:23.276296Z","link":"https://www.novartis.com//clinicaltrials/study/nct04795427","source":"Novartis","relevant":null},{"trial_id":706,"title":"A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hoffmann-La Roche&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-03-07T17:00:00Z","discovery_date":"2022-03-09T00:29:14.458003Z","link":"https://clinicaltrials.gov/ct2/show/NCT05269004?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":593,"title":"Function Magnetic Resonance Imaging to Assess Two Therapeutic Strategies in Multiple Sclerosis (NeuroRehEM).","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: N-back Cognitive Training;   Behavioral: Virtual Reality Motor and Cognitive Training&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Universitat Jaume I&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-03-08T17:00:00Z","discovery_date":"2022-03-08T15:25:06.601663Z","link":"https://clinicaltrials.gov/ct2/show/NCT05270239?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":592,"title":"Covid-19 Vaccine Immune Response in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Blood Test 1;   Other: Blood Test 2&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University Hospitals of North Midlands NHS Trust&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-03-08T17:00:00Z","discovery_date":"2022-03-08T15:25:06.599812Z","link":"https://clinicaltrials.gov/ct2/show/NCT05269888?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":591,"title":"Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Sleep;   Pain&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Cannabidiol (CBD);   Drug: Tetrahydrocannabinol (THC);   Drug: Placebo CBD;   Drug: Placebo THC&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Tiffany J. Braley, MD, MS;   National Center for Complementary and Integrative Health (NCCIH)&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-03-08T17:00:00Z","discovery_date":"2022-03-08T15:25:06.595685Z","link":"https://clinicaltrials.gov/ct2/show/NCT05269628?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":427,"title":"Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Ofatumumab;   Other: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-03-04T17:00:00Z","discovery_date":"2022-03-04T17:22:45Z","link":"https://clinicaltrials.gov/ct2/show/NCT05266469?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":426,"title":"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Natalizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Biogen&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-03-03T17:00:00Z","discovery_date":"2022-03-03T12:52:45Z","link":"https://clinicaltrials.gov/ct2/show/NCT05265728?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":425,"title":"Exploring Cortical Remyelination in Children With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Children With Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: MRI without injection of contrast product&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Assistance Publique - Hôpitaux de Paris&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-28T17:00:00Z","discovery_date":"2022-02-28T22:52:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT05258396?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":424,"title":"Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Michigan;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Wayne State University;   University of Washington&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-23T17:00:00Z","discovery_date":"2022-02-23T16:12:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT05252195?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":422,"title":"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors","summary":"","published_date":"2022-02-21T23:55:32Z","discovery_date":"2022-02-21T23:55:32Z","link":"https://www.novartis.com/clinicaltrials/study/nct04795427","source":"Novartis","relevant":null},{"trial_id":423,"title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan","summary":"","published_date":"2022-02-21T23:55:32Z","discovery_date":"2022-02-21T23:55:32Z","link":"https://www.novartis.com/clinicaltrials/study/nct05114746","source":"Novartis","relevant":null},{"trial_id":421,"title":"Study of Gynecological Follow-up Concerning Women With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Questionnaire&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Bordeaux;   Merck Sharp &amp; Dohme Corp.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-21T17:00:00Z","discovery_date":"2022-02-21T13:32:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT05248438?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":419,"title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4&#x2F;6 Inhibitor and an Aromatase Inhibitor.","summary":"","published_date":"2022-02-19T21:55:32Z","discovery_date":"2022-02-19T21:55:32Z","link":"https://www.novartis.com/clinicaltrials/study/nct05038735","source":"Novartis","relevant":null},{"trial_id":420,"title":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","summary":"","published_date":"2022-02-19T21:55:32Z","discovery_date":"2022-02-19T21:55:32Z","link":"https://www.novartis.com/clinicaltrials/study/nct04417621","source":"Novartis","relevant":null},{"trial_id":414,"title":"Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies","summary":"","published_date":"2022-02-19T01:55:33Z","discovery_date":"2022-02-19T01:55:33Z","link":"https://www.novartis.com/clinicaltrials/study/nct04000529","source":"Novartis","relevant":null},{"trial_id":418,"title":"A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP","summary":"","published_date":"2022-02-19T01:55:33Z","discovery_date":"2022-02-19T01:55:33Z","link":"https://www.novartis.com/clinicaltrials/study/nct04346654","source":"Novartis","relevant":null},{"trial_id":417,"title":"Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)","summary":"","published_date":"2022-02-19T01:55:33Z","discovery_date":"2022-02-19T01:55:33Z","link":"https://www.novartis.com/clinicaltrials/study/nct04980833","source":"Novartis","relevant":null},{"trial_id":416,"title":"Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy","summary":"","published_date":"2022-02-19T01:55:33Z","discovery_date":"2022-02-19T01:55:33Z","link":"https://www.novartis.com/clinicaltrials/study/nct04816214","source":"Novartis","relevant":null},{"trial_id":415,"title":"Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer","summary":"","published_date":"2022-02-19T01:55:33Z","discovery_date":"2022-02-19T01:55:33Z","link":"https://www.novartis.com/clinicaltrials/study/nct04940052","source":"Novartis","relevant":null},{"trial_id":413,"title":"The Effect of Iyengar Yoga Practice on Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Iyengar Yoga;   Yoga;   EDSS&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: The effect of Iyengar yoga practice on patients with multiple sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University Hospital, Motol&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-18T17:00:00Z","discovery_date":"2022-02-18T13:53:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05247372?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":412,"title":"Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2","summary":"","published_date":"2022-02-17T20:46:49Z","discovery_date":"2022-02-17T20:46:49Z","link":"https://www.novartis.com/clinicaltrials/study/nct04935359","source":"Novartis","relevant":null},{"trial_id":411,"title":"Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Relapsing-Remitting Multiple Sclerosis (RRMS);   Neuromyelitis Optica;   Healthy&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Procedure: Peripheral blood withdrawal&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Neuromed IRCCS;   University of Rome Tor Vergata&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-17T17:00:00Z","discovery_date":"2022-02-17T12:33:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05245344?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":410,"title":"Sensing Physical Activity to Evaluate and Monitor a Routine Aftercare Program (SensE-M)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Disease With a Risk for Chronicity&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Zurich;   Kliniken Valens&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-17T17:00:00Z","discovery_date":"2022-02-17T12:33:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05243407?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":409,"title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines","summary":"","published_date":"2022-02-17T05:46:47Z","discovery_date":"2022-02-17T05:46:47Z","link":"https://www.novartis.com/clinicaltrials/study/nct05030311","source":"Novartis","relevant":null},{"trial_id":406,"title":"Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Remitting Multiple Sclerosis (RRMS)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Pegylated interferon beta-1a;   Drug: Interferon Beta-1A Prefilled Syringe&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Cinnagen&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-16T17:00:00Z","discovery_date":"2022-02-16T14:23:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05242133?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":407,"title":"Telemonitoring and Connected Care Applied to Multiple Sclerose","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: MSmonitor, a self-management&#x2F;education program with e-health interventions;   Device: Video calling program &quot;Better-close&quot;;   Device: Researchmanager program&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Isala&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-16T17:00:00Z","discovery_date":"2022-02-16T14:23:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05242731?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":405,"title":"To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","summary":"","published_date":"2022-02-15T03:46:48Z","discovery_date":"2022-02-15T03:46:48Z","link":"https://www.novartis.com/clinicaltrials/study/nct04058067","source":"Novartis","relevant":null},{"trial_id":404,"title":"Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)","summary":"","published_date":"2022-02-15T03:46:48Z","discovery_date":"2022-02-15T03:46:48Z","link":"https://www.novartis.com/clinicaltrials/study/nct05089656","source":"Novartis","relevant":null},{"trial_id":403,"title":"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant","summary":"","published_date":"2022-02-15T03:46:48Z","discovery_date":"2022-02-15T03:46:48Z","link":"https://www.novartis.com/clinicaltrials/study/nct04899349","source":"Novartis","relevant":null},{"trial_id":402,"title":"Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria","summary":"","published_date":"2022-02-11T19:46:49Z","discovery_date":"2022-02-11T19:46:49Z","link":"https://www.novartis.com/clinicaltrials/study/nct04747613","source":"Novartis","relevant":null},{"trial_id":401,"title":"TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Natalizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Biogen;   Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-11T17:00:00Z","discovery_date":"2022-02-11T14:03:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05236777?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":398,"title":"A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China","summary":"","published_date":"2022-02-10T23:46:50Z","discovery_date":"2022-02-10T23:46:50Z","link":"https://www.novartis.com/clinicaltrials/study/nct04894890","source":"Novartis","relevant":null},{"trial_id":399,"title":"Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","summary":"","published_date":"2022-02-10T23:46:50Z","discovery_date":"2022-02-10T23:46:50Z","link":"https://www.novartis.com/clinicaltrials/study/nct04268823","source":"Novartis","relevant":null},{"trial_id":400,"title":"An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study","summary":"","published_date":"2022-02-10T23:46:50Z","discovery_date":"2022-02-10T23:46:50Z","link":"https://www.novartis.com/clinicaltrials/study/nct04597632","source":"Novartis","relevant":null},{"trial_id":397,"title":"Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia","summary":"","published_date":"2022-02-10T23:46:50Z","discovery_date":"2022-02-10T23:46:50Z","link":"https://www.novartis.com/clinicaltrials/study/nct04784390","source":"Novartis","relevant":null},{"trial_id":396,"title":"A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)","summary":"","published_date":"2022-02-10T13:46:49Z","discovery_date":"2022-02-10T13:46:49Z","link":"https://www.novartis.com/clinicaltrials/study/nct04737330","source":"Novartis","relevant":null},{"trial_id":394,"title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis;   Primary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ocrelizumab IV;   Drug: Ocrelizumab SC;   Drug: Methylprednisolone IV;   Drug: Diphenhydramine IV;   Drug: Dexamethasone given orally;   Drug: Desloratadine given orally&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hoffmann-La Roche&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-10T17:00:00Z","discovery_date":"2022-02-10T12:43:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05232825?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":395,"title":"The Feasibility of Frame Running as an Exercise Option for People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Frame Running&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Queen Margaret University;   Multiple Sclerosis Society&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-10T17:00:00Z","discovery_date":"2022-02-10T12:43:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05234879?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":393,"title":"A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+&#x2F;HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia","summary":"","published_date":"2022-02-10T03:46:48Z","discovery_date":"2022-02-10T03:46:48Z","link":"https://www.novartis.com/clinicaltrials/study/nct04943497","source":"Novartis","relevant":null},{"trial_id":392,"title":"Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant","summary":"","published_date":"2022-02-10T03:46:48Z","discovery_date":"2022-02-10T03:46:48Z","link":"https://www.novartis.com/clinicaltrials/study/nct04862143","source":"Novartis","relevant":null},{"trial_id":391,"title":"STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS","summary":"","published_date":"2022-02-10T03:46:48Z","discovery_date":"2022-02-10T03:46:48Z","link":"https://www.novartis.com/clinicaltrials/study/nct04878432","source":"Novartis","relevant":null},{"trial_id":390,"title":"Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma","summary":"","published_date":"2022-02-09T17:46:50Z","discovery_date":"2022-02-09T17:46:50Z","link":"https://www.novartis.com/clinicaltrials/study/nct04903197","source":"Novartis","relevant":null},{"trial_id":389,"title":"CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril&#x2F;Valsartan in Pediatric Patients With HF","summary":"","published_date":"2022-02-09T17:46:50Z","discovery_date":"2022-02-09T17:46:50Z","link":"https://www.novartis.com/clinicaltrials/study/nct03785405","source":"Novartis","relevant":null},{"trial_id":388,"title":"Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease","summary":"","published_date":"2022-02-09T07:46:49Z","discovery_date":"2022-02-09T07:46:49Z","link":"https://www.novartis.com/clinicaltrials/study/nct05030428","source":"Novartis","relevant":null},{"trial_id":386,"title":"Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.","summary":"","published_date":"2022-02-08T21:46:49Z","discovery_date":"2022-02-08T21:46:49Z","link":"https://www.novartis.com/clinicaltrials/study/nct05078580","source":"Novartis","relevant":null},{"trial_id":385,"title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","summary":"","published_date":"2022-02-08T21:46:49Z","discovery_date":"2022-02-08T21:46:49Z","link":"https://www.novartis.com/clinicaltrials/study/nct04699188","source":"Novartis","relevant":null},{"trial_id":387,"title":"Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy","summary":"","published_date":"2022-02-08T21:46:49Z","discovery_date":"2022-02-08T21:46:49Z","link":"https://www.novartis.com/clinicaltrials/study/nct04984876","source":"Novartis","relevant":null},{"trial_id":384,"title":"The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Primary Progressive Multiple Sclerosis;   Exercise;   Cardiorespiratory Fitness&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: HIIT;   Behavioral: MCT&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Klinik Valens;   Technische Universität Dortmund, Germany&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-08T17:00:00Z","discovery_date":"2022-02-08T13:13:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05229861?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":383,"title":"Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients","summary":"","published_date":"2022-02-07T20:46:47Z","discovery_date":"2022-02-07T20:46:47Z","link":"https://www.novartis.com/clinicaltrials/study/nct03656562","source":"Novartis","relevant":null},{"trial_id":382,"title":"Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection","summary":"","published_date":"2022-02-07T20:46:47Z","discovery_date":"2022-02-07T20:46:47Z","link":"https://www.novartis.com/clinicaltrials/study/nct04838626","source":"Novartis","relevant":null},{"trial_id":381,"title":"3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: 3D OPTIMIZED WMN MPRAGE&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University Hospital, Bordeaux&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-07T17:00:00Z","discovery_date":"2022-02-07T15:03:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05227092?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":380,"title":"Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer&#39;s Disease","summary":"","published_date":"2022-02-05T10:10:47Z","discovery_date":"2022-02-05T10:10:47Z","link":"https://www.novartis.com/clinicaltrials/study/nct04795466","source":"Novartis","relevant":null},{"trial_id":378,"title":"Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.","summary":"","published_date":"2022-02-05T10:10:47Z","discovery_date":"2022-02-05T10:10:47Z","link":"https://www.novartis.com/clinicaltrials/study/nct04774926","source":"Novartis","relevant":null},{"trial_id":377,"title":"Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects","summary":"","published_date":"2022-02-05T00:10:44Z","discovery_date":"2022-02-05T00:10:44Z","link":"https://www.novartis.com/clinicaltrials/study/nct04129528","source":"Novartis","relevant":null},{"trial_id":376,"title":"A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070&#x2F;Branaplam in Early Manifest Huntington&#39;s Disease","summary":"","published_date":"2022-02-05T00:10:44Z","discovery_date":"2022-02-05T00:10:44Z","link":"https://www.novartis.com/clinicaltrials/study/nct05111249","source":"Novartis","relevant":null},{"trial_id":375,"title":"A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration","summary":"","published_date":"2022-02-05T00:10:44Z","discovery_date":"2022-02-05T00:10:44Z","link":"https://www.novartis.com/clinicaltrials/study/nct04239027","source":"Novartis","relevant":null},{"trial_id":373,"title":"Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Acceptance and Commitment Therapy&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Nottingham&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-04T17:00:00Z","discovery_date":"2022-02-04T15:47:25Z","link":"https://clinicaltrials.gov/ct2/show/NCT05225012?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":372,"title":"Evaluation of Relapse Presence in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis Relapse&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: in-vivo Corneal Confocal Microscopy&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Marmara University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2022-02-01T17:00:00Z","discovery_date":"2022-02-01T14:57:18Z","link":"https://clinicaltrials.gov/ct2/show/NCT05218317?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":371,"title":"Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: partial-body cryotherapy chamber session&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Fondation Ildys;   Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-02-01T17:00:00Z","discovery_date":"2022-02-01T14:57:18Z","link":"https://clinicaltrials.gov/ct2/show/NCT05219201?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":370,"title":"Promoting Aerobic Training in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Aerobic exercise;   Behavioral: Task-oriented upper-limb training;   Behavioral: Sport events participation&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Fondazione Italiana Sclerosi Multipla;   University of Genoa;   University Grenoble Alps&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-28T17:00:00Z","discovery_date":"2022-01-28T15:57:18Z","link":"https://clinicaltrials.gov/ct2/show/NCT05212805?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":368,"title":"Safety of Exposure to Natalizumab During Pregnancy","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Questionnaire&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Bordeaux;   Biogen&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-27T17:00:00Z","discovery_date":"2022-01-27T17:47:18Z","link":"https://clinicaltrials.gov/ct2/show/NCT05209815?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":369,"title":"LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Centre Hospitalier Universitaire de Nice&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-27T17:00:00Z","discovery_date":"2022-01-27T17:47:18Z","link":"https://clinicaltrials.gov/ct2/show/NCT05210621?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":366,"title":"A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hoffmann-La Roche&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-26T17:00:00Z","discovery_date":"2022-01-26T13:17:18Z","link":"https://clinicaltrials.gov/ct2/show/NCT05208840?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":367,"title":"Development and Evaluation of the Self-management Module in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Self Efficacy&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Education&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hacettepe University&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-26T17:00:00Z","discovery_date":"2022-01-26T13:17:18Z","link":"https://clinicaltrials.gov/ct2/show/NCT05209113?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":365,"title":"MS-ResearchBiomarkerS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive;   Clinically Isolated Syndrome;   Radiologically Isolated Syndrome;   Neuromyelitis Optica Spectrum Disorders;   Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease;   Neurologic Autoimmune Disease;   Neurologic Disorder;   Healthy Aging&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Cedars-Sinai Medical Center&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-24T17:00:00Z","discovery_date":"2022-01-24T16:57:17Z","link":"https://clinicaltrials.gov/ct2/show/NCT05204459?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":364,"title":"Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: IMU-838 tablets;   Drug: Placebo matching IMU-838 tablets&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Immunic AG&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-21T17:00:00Z","discovery_date":"2022-01-21T14:40:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05201638?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":363,"title":"Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: Ofatumumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-20T17:00:00Z","discovery_date":"2022-01-20T16:30:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT05199571?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":361,"title":"Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Biogen&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-19T17:00:00Z","discovery_date":"2022-01-19T17:16:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05197699?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":362,"title":"Expression of PARP-1 in Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Genetic: Blood sampling&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sohag University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-19T17:00:00Z","discovery_date":"2022-01-19T17:16:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05196425?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":360,"title":"Reinventing Yourself With Multiple Sclerosis (MS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Reinvention with MS&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Kessler Foundation;   Craig Hospital;   University of Minnesota&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-17T17:00:00Z","discovery_date":"2022-01-18T12:46:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05195320?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":359,"title":"Validity and Reliability of the Dual-task Questionnaire","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Procedure: validity and reability study&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Gazi University&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-12T17:00:00Z","discovery_date":"2022-01-12T15:40:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05188937?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":358,"title":"Investigating the Home-based RCTs of Pilates Exercises and Cognitive Rehabilitation Exercises for Executive Functions and Anxiety in MS.","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Home-Based Pilates exercise;   Other: Home-based Cognitive Rehabilitation;   Other: waiting list group&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Arak University of Medical Sciences;   Pardis Specialized Wellness Institute&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-11T17:00:00Z","discovery_date":"2022-01-11T17:30:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05185986?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":357,"title":"Validity and Reliability of Turkish Version Leg Activity Measure","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Spinal Cord Injuries;   Multiple Sclerosis;   Stroke&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: assessment&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Kahramanmaras Sutcu Imam University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-07T17:00:00Z","discovery_date":"2022-01-10T13:00:20Z","link":"https://clinicaltrials.gov/ct2/show/NCT05182411?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":356,"title":"Validity and Reliability of the Modified Four Square Step Test in Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Assesment&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Kahramanmaras Sutcu Imam University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-07T17:00:00Z","discovery_date":"2022-01-10T13:00:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05182398?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":355,"title":"Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Monomethyl Fumarate 190 Mg;   Drug: Diroximel Fumarate 462 mg&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Banner Life Sciences LLC&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2022-01-06T17:00:00Z","discovery_date":"2022-01-06T23:30:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05181215?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":354,"title":"Natalizumab and Chronic Inflammation","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Natalizumab 300 MG in 15 ML Injection&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Vanderbilt University Medical Center;   Biogen&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-05T17:00:00Z","discovery_date":"2022-01-05T12:40:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05177718?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":352,"title":"A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Spasticity&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Arbaclofen;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    RVL Pharmaceuticals, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-05T17:00:00Z","discovery_date":"2022-01-05T12:40:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05179577?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":353,"title":"Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Training Study;   Multiple Sclerosis;   Blood Flow Restriction&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Blood Flow Restriction;   Other: Standard of Care&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Central Florida;   AdventHealth&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-05T17:00:00Z","discovery_date":"2022-01-05T12:40:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05177952?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":351,"title":"Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS);   Relapsing-remitting Multiple Sclerosis (RRMS);   Secondary-progressive Multiple Sclerosis (SPMS);   Primary Progressive Multiple Sclerosis (PPMS)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Diagnostic Test: MRI;   Other: Neurocognitive examination for healthy subjects;   Other: blood sampling&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Basel, Switzerland;   Swiss National Science Foundation&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2022-01-04T17:00:00Z","discovery_date":"2022-01-04T14:30:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05177523?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":350,"title":"Adherence to Mediterranean Diet and Cardiovascular Health in Multiple Sclerosis Female Patients: a Case Control Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Lifestyle intervention&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Iaso Maternity Hospital, Athens, Greece;   Harokopio University;   G.Gennimatas General Hospital&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-12-31T17:00:00Z","discovery_date":"2022-01-03T16:20:19Z","link":"https://clinicaltrials.gov/ct2/show/NCT05175378?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":349,"title":"Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ofatumumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Southern California;   Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-29T17:00:00Z","discovery_date":"2021-12-29T15:24:10Z","link":"https://clinicaltrials.gov/ct2/show/NCT05171972?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":348,"title":"Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing-remitting Multiple Sclerosis (RRMS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: BeCare application&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Icahn School of Medicine at Mount Sinai&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-29T17:00:00Z","discovery_date":"2021-12-29T15:24:10Z","link":"https://clinicaltrials.gov/ct2/show/NCT05172466?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":347,"title":"A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Bristol-Myers Squibb&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-24T17:00:00Z","discovery_date":"2021-12-27T15:42:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05170126?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":346,"title":"Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Combination Product: Extracorporeal Photopheresis;   Combination Product: MS standard of care&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Abu Dhabi Stem Cells Center&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-23T17:00:00Z","discovery_date":"2021-12-23T15:29:41Z","link":"https://clinicaltrials.gov/ct2/show/NCT05168384?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":345,"title":"Impact Program for Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Impact of four week coaching program on dietary habits&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Alabama at Birmingham&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-21T17:00:00Z","discovery_date":"2021-12-21T15:17:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05165238?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":344,"title":"Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Healthy&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Procedure: thoracic duct cannulation&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Pennsylvania;   Novartis Pharmaceuticals;   Novartis Institutes for BioMedical Research&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-17T17:00:00Z","discovery_date":"2021-12-17T16:17:56Z","link":"https://clinicaltrials.gov/ct2/show/NCT05162638?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":343,"title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Remibrutinib;   Drug: Teriflunomide&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-14T17:00:00Z","discovery_date":"2021-12-14T12:17:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05156281?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":342,"title":"Safety of Therapeutic Step-down in Neuromyelitis Optica","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Neuromyelitis Optica&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University Hospital, Strasbourg, France&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-13T17:00:00Z","discovery_date":"2021-12-13T14:07:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05155644?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":341,"title":"China National Registry of CNS Inflammatory Demyelinating Diseases","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   NMO Spectrum Disorder;   Clinically Isolated Syndrome;   CNS Demyelinating Autoimmune Diseases;   Acute Disseminated Encephalomyelitis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Intravenous steroid&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Beijing Tiantan Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-13T17:00:00Z","discovery_date":"2021-12-13T14:07:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05154370?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":339,"title":"Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Inflammatory Disease&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Procedure: PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Assistance Publique - Hôpitaux de Paris&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-07T17:00:00Z","discovery_date":"2021-12-07T13:52:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT05147532?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":340,"title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Remibrutinib;   Drug: Teriflunomide&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-07T17:00:00Z","discovery_date":"2021-12-07T13:52:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT05147220?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":338,"title":"Impact of Fingolimod Adherence on Outcomes","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Fingolimod&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-12-02T17:00:00Z","discovery_date":"2021-12-02T15:12:45Z","link":"https://clinicaltrials.gov/ct2/show/NCT05141669?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":337,"title":"Pilot Study on EEG and Behavioral Effects of Two Different Treatments on Sexual Life","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Spinal Cord Injuries&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Therapy&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    IRCCS San Camillo, Venezia, Italy&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-12-02T17:00:00Z","discovery_date":"2021-12-02T15:12:45Z","link":"https://clinicaltrials.gov/ct2/show/NCT05142111?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":336,"title":"Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: IMU-838 tablets;   Drug: Placebo matching IMU-838 tablets&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Immunic AG&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-25T17:00:00Z","discovery_date":"2021-11-26T16:07:43Z","link":"https://clinicaltrials.gov/ct2/show/NCT05134441?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":333,"title":"Ocrelizumab Access by Socio-Economic Status","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Brigham and Women&#39;s Hospital;   Genentech, Inc.;   Boston Medical Center&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-23T17:00:00Z","discovery_date":"2021-11-23T15:17:43Z","link":"https://clinicaltrials.gov/ct2/show/NCT05131984?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":334,"title":"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: GSK3888130B;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    GlaxoSmithKline&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-23T17:00:00Z","discovery_date":"2021-11-23T15:17:43Z","link":"https://clinicaltrials.gov/ct2/show/NCT05131971?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":335,"title":"CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Metformin and clemastine in combination;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Cambridge University Hospitals NHS Foundation Trust;   University of Cambridge&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-23T17:00:00Z","discovery_date":"2021-11-23T15:17:43Z","link":"https://clinicaltrials.gov/ct2/show/NCT05131828?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":332,"title":"Improving Prospective Memory Via Telehealth","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Prospective Memory Intervention;   Behavioral: Educational&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Saint Francis Care&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-22T17:00:00Z","discovery_date":"2021-11-22T13:57:43Z","link":"https://clinicaltrials.gov/ct2/show/NCT05129293?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":330,"title":"A Health Action Process Approach Online Intervention for People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: MSPA eClass&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Illinois at Urbana-Champaign&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-18T17:00:00Z","discovery_date":"2021-11-18T18:07:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05124522?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":331,"title":"An Individualized-health eLibrary App for People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: SavvyHealth&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Illinois at Urbana-Champaign&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-18T17:00:00Z","discovery_date":"2021-11-18T18:07:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05124600?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":328,"title":"Respiratory Functions in Pediatric-Onset Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Pediatric-onset Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Evaluation of respiratory capacity, respiratory muscle strength and fatigue&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Istanbul University-Cerrahpasa&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-17T17:00:00Z","discovery_date":"2021-11-17T13:37:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05123924?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":327,"title":"A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing-Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ocrelizumab;   Other: Ocrelizumab Placebo;   Drug: Fingolimod;   Other: Fingolimod Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hoffmann-La Roche;   PPD&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-17T17:00:00Z","discovery_date":"2021-11-17T13:37:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05123703?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":329,"title":"Longitudinal Assessment of Iron Rims in MS Lesions","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Blood sample provided;   Diagnostic Test: 7-T MRI scan&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Nottingham University Hospitals NHS Trust;   Johns Hopkins University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-17T17:00:00Z","discovery_date":"2021-11-17T13:37:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05123443?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":325,"title":"Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: N-acetyl cysteine;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Emmanuelle Waubant;   United States Department of Defense&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-16T17:00:00Z","discovery_date":"2021-11-16T12:17:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05122559?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":326,"title":"COVID-19 Vaccine Biomarker Study in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   COVID-19&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Columbia University;   Novartis&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-16T17:00:00Z","discovery_date":"2021-11-16T12:17:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05121662?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":324,"title":"A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: fenebrutinib;   Drug: placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hoffmann-La Roche&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-15T17:00:00Z","discovery_date":"2021-11-15T14:07:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05119569?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":323,"title":"A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants","summary":"","published_date":"2021-11-12T15:31:05Z","discovery_date":"2021-11-12T15:31:05Z","link":"https://www.novartis.com/clinicaltrials/study/nct04812548","source":"Novartis","relevant":null},{"trial_id":322,"title":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","summary":"","published_date":"2021-11-12T15:31:05Z","discovery_date":"2021-11-12T15:31:05Z","link":"https://www.novartis.com/clinicaltrials/study/nct04925479","source":"Novartis","relevant":null},{"trial_id":321,"title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients","summary":"","published_date":"2021-11-12T15:31:05Z","discovery_date":"2021-11-12T15:31:05Z","link":"https://www.novartis.com/clinicaltrials/study/nct04635800","source":"Novartis","relevant":null},{"trial_id":320,"title":"Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)","summary":"","published_date":"2021-11-11T19:31:04Z","discovery_date":"2021-11-11T19:31:04Z","link":"https://www.novartis.com/clinicaltrials/study/nct04147195","source":"Novartis","relevant":null},{"trial_id":319,"title":"Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: HB-adMSCs;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hope Biosciences Stem Cell Research Foundation&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-11T17:00:00Z","discovery_date":"2021-11-11T15:07:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT05116540?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":318,"title":"Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation","summary":"","published_date":"2021-11-11T09:31:04Z","discovery_date":"2021-11-11T09:31:04Z","link":"https://www.novartis.com/clinicaltrials/study/nct04427072","source":"Novartis","relevant":null},{"trial_id":317,"title":"DFF332 as a Single Agent and in Combination With Everolimus &amp; Immuno-Oncology Agents in Advanced&#x2F;Relapsed Renal Cancer &amp; Other Malignancies","summary":"","published_date":"2021-11-10T23:31:04Z","discovery_date":"2021-11-10T23:31:04Z","link":"https://www.novartis.com/clinicaltrials/study/nct04895748","source":"Novartis","relevant":null},{"trial_id":314,"title":"A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy","summary":"","published_date":"2021-11-10T13:31:04Z","discovery_date":"2021-11-10T13:31:04Z","link":"https://www.novartis.com/clinicaltrials/study/nct04150029","source":"Novartis","relevant":null},{"trial_id":316,"title":"Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study","summary":"","published_date":"2021-11-10T13:31:04Z","discovery_date":"2021-11-10T13:31:04Z","link":"https://www.novartis.com/clinicaltrials/study/nct04657822","source":"Novartis","relevant":null},{"trial_id":315,"title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","summary":"","published_date":"2021-11-10T13:31:04Z","discovery_date":"2021-11-10T13:31:04Z","link":"https://www.novartis.com/clinicaltrials/study/nct04971226","source":"Novartis","relevant":null},{"trial_id":311,"title":"Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Diagnostic Test: Measurement of concentrations of orally-used DMDs;   Diagnostic Test: Genetic testing;   Diagnostic Test: Parameters for routine use of DMDs;   Other: Side effects of orally used DMDs&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital Ostrava;   University of Ostrava&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-09T17:00:00Z","discovery_date":"2021-11-09T12:26:59Z","link":"https://clinicaltrials.gov/ct2/show/NCT05112484?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":310,"title":"Electrical Stimulations on Pain, Functional Capacity and Quality of Life in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Electrotherapy&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Kahramanmaras Sutcu Imam University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-08T17:00:00Z","discovery_date":"2021-11-08T14:27:35Z","link":"https://clinicaltrials.gov/ct2/show/NCT05110586?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":309,"title":"A Study to Evaluate White Matter Hyperintensities in Migraine","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Migraine;   Small Vessel Ischemic Disease;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Brain Neuroimaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Mayo Clinic&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-08T17:00:00Z","discovery_date":"2021-11-08T14:27:34Z","link":"https://clinicaltrials.gov/ct2/show/NCT05112289?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":306,"title":"Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.","summary":"","published_date":"2021-11-07T17:02:39Z","discovery_date":"2021-11-07T17:02:39Z","link":"https://www.novartis.com/clinicaltrials/study/nct04948333","source":"Novartis","relevant":null},{"trial_id":307,"title":"Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC","summary":"","published_date":"2021-11-07T17:02:39Z","discovery_date":"2021-11-07T17:02:39Z","link":"https://www.novartis.com/clinicaltrials/study/nct04926831","source":"Novartis","relevant":null},{"trial_id":305,"title":"Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis","summary":"","published_date":"2021-11-06T07:04:31Z","discovery_date":"2021-11-06T07:04:31Z","link":"https://www.novartis.com/clinicaltrials/study/nct04886258","source":"Novartis","relevant":null},{"trial_id":301,"title":"Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments","summary":"","published_date":"2021-11-04T20:04:29Z","discovery_date":"2021-11-04T20:04:29Z","link":"https://www.novartis.com/clinicaltrials/study/nct04058756","source":"Novartis","relevant":null},{"trial_id":300,"title":"A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors","summary":"","published_date":"2021-11-04T20:04:29Z","discovery_date":"2021-11-04T20:04:29Z","link":"https://www.novartis.com/clinicaltrials/study/nct04857372","source":"Novartis","relevant":null},{"trial_id":303,"title":"Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma","summary":"","published_date":"2021-11-04T20:04:29Z","discovery_date":"2021-11-04T20:04:29Z","link":"https://www.novartis.com/clinicaltrials/study/nct04946318","source":"Novartis","relevant":null},{"trial_id":302,"title":"A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC","summary":"","published_date":"2021-11-04T20:04:29Z","discovery_date":"2021-11-04T20:04:29Z","link":"https://www.novartis.com/clinicaltrials/study/nct04452877","source":"Novartis","relevant":null},{"trial_id":299,"title":"A Sub-Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: Konectom platform&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Biogen&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-11-03T16:00:00Z","discovery_date":"2021-11-03T12:21:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05106465?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":298,"title":"Robotics for Mobility Rehabilitation in MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   MS&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Balance exercise program using exoskeleton device&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    East Kent Hospitals University NHS Foundation Trust&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-11-01T16:00:00Z","discovery_date":"2021-11-01T12:51:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05102682?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":297,"title":"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Alopecia Areata;   Alopecia Totalis;   Alopecia Universalis;   Alopecia Areata (&amp; Ophiasis);   Alopecia Barbae;   Alopecia Diffuse;   Autoimmune Diseases;   Autoimmune Hyperthyroidism;   Autoimmune Hypothyroidism;   Diabetes Mellitus, Type 1;   Ulcerative Colitis;   Inflammatory Bowel Diseases;   Crohn Disease;   Rheumatoid Arthritis;   Down Syndrome;   Atopic Dermatitis;   Atopic Asthma;   Atopic Rhinitis;   Vitiligo;   Psoriasis;   Ankylosing Spondylitis;   Multiple Sclerosis;   Lupus Erythematosus;   COVID-19 Pandemic;   Vaccine Reaction;   Infections;   Anemia, Pernicious&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Exposure of interest&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Faculty Hospital Kralovske Vinohrady&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-28T16:00:00Z","discovery_date":"2021-10-28T13:51:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05098600?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":296,"title":"MS Spinal Mobilisation Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Spinal Mobilisation Intervention;   Other: General Massage&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Edinburgh Napier University;   Scottish Hospital Endowments Research Trust;   Pacla Medical Ltd&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-10-25T16:00:00Z","discovery_date":"2021-10-25T13:01:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05090709?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":295,"title":"Cannabis as a Complementary Treatment in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Cannabis oil vs placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Centre hospitalier de l&#39;Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR);   Multiple Sclerosis Society of Canada&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-25T16:00:00Z","discovery_date":"2021-10-25T13:01:07Z","link":"https://clinicaltrials.gov/ct2/show/NCT05092191?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":293,"title":"Diagnosic and Pronostic Values of Kappa and Lambda Free Light Chains in Central Nervous System Inflammatory Diseases","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Central Nervous System Diseases;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Biological collection&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Centre Hospitalier Universitaire de Nice&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-22T16:00:00Z","discovery_date":"2021-10-22T12:11:07Z","link":"https://clinicaltrials.gov/ct2/show/NCT05088473?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":294,"title":"A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing-Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ofatumumab;   Drug: Disease modifying treatment (DMT)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-22T16:00:00Z","discovery_date":"2021-10-22T12:11:07Z","link":"https://clinicaltrials.gov/ct2/show/NCT05090371?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":292,"title":"Characterizing the Use of Ofatumumab in a Real World Setting","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: ofatumumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-22T16:00:00Z","discovery_date":"2021-10-22T12:11:07Z","link":"https://clinicaltrials.gov/ct2/show/NCT05090033?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":291,"title":"Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapse Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ofatumumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-20T16:00:00Z","discovery_date":"2021-10-20T12:41:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05084638?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":290,"title":"A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Forms of Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Diroximel fumarate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Biogen&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-19T16:00:00Z","discovery_date":"2021-10-19T13:59:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05083923?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":288,"title":"A Systems Approach to Understanding Disease Processes in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: All patients in the study will be treated with ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Providence Health &amp; Services;   Institute for Systems Biology;   Genentech, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-18T16:00:00Z","discovery_date":"2021-10-18T12:39:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05081700?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":289,"title":"COVID-19 Booster Vaccination in Persons With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    PWMS Who Have Completed Vaccination Against COVID-19 and Test Negative for COVID-19 Spike Protein Antibodies Using a Commercial Assay&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Homologous booster;   Biological: Heterologous booster&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Griffin Hospital;   Yale-Griffin Prevention Research Center&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-18T16:00:00Z","discovery_date":"2021-10-18T12:39:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05081271?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":287,"title":"Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: Tolerogenic Fibroblasts&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    FibroBiologics&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-10-15T16:00:00Z","discovery_date":"2021-10-15T14:59:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05080270?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":286,"title":"Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.","summary":"","published_date":"2021-10-14T22:52:38Z","discovery_date":"2021-10-14T22:52:38Z","link":"https://www.novartis.com/clinicaltrials/study/nct04817618","source":"Novartis","relevant":null},{"trial_id":284,"title":"Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Cerebrospinal and Blood Serum Semaphorin 4A Levels&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Providence Health &amp; Services;   Milton S. Hershey Medical Center;   Bristol-Myers Squibb&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-14T16:00:00Z","discovery_date":"2021-10-14T16:49:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05077956?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":285,"title":"Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Rituximab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    St. Petersburg State Pavlov Medical University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-14T16:00:00Z","discovery_date":"2021-10-14T16:49:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05078177?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":283,"title":"Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Urinary Bladder, Neurogenic&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Initial management of the urinary disorder&#x2F;s identified during the screening phase&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    ASP 7 Ragusa&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-13T16:00:00Z","discovery_date":"2021-10-13T13:56:18Z","link":"https://clinicaltrials.gov/ct2/show/NCT05075642?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":282,"title":"Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: COVID-19 vaccination&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Sheba Medical Center;   Sanofi&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-12T16:00:00Z","discovery_date":"2021-10-12T15:46:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05075499?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":281,"title":"Study of Diagnostic Performance of [18F]CTT1057 in BCR","summary":"","published_date":"2021-10-12T00:09:39Z","discovery_date":"2021-10-12T00:09:39Z","link":"https://www.novartis.com/clinicaltrials/study/nct04838613","source":"Novartis","relevant":null},{"trial_id":280,"title":"Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: CSF immunoglobulin (Ig) free light chains (FLC) dosage&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Francis Corazza&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-11T16:00:00Z","discovery_date":"2021-10-11T14:26:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05072691?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":279,"title":"Telerehabilitation-based Upper Extremity Training in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Telerehabilitation-based Upper Extremity Training&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Dokuz Eylul University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-11T16:00:00Z","discovery_date":"2021-10-11T14:26:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05073731?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":278,"title":"Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)","summary":"","published_date":"2021-10-10T08:09:39Z","discovery_date":"2021-10-10T08:09:39Z","link":"https://www.novartis.com/clinicaltrials/study/nct04851873","source":"Novartis","relevant":null},{"trial_id":277,"title":"Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy","summary":"","published_date":"2021-10-09T12:10:27Z","discovery_date":"2021-10-09T12:10:27Z","link":"https://www.novartis.com/clinicaltrials/study/nct04820530","source":"Novartis","relevant":null},{"trial_id":275,"title":"Study of Efficacy of Oral Sacubitril&#x2F;Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy","summary":"","published_date":"2021-10-08T16:09:38Z","discovery_date":"2021-10-08T16:09:38Z","link":"https://www.novartis.com/clinicaltrials/study/nct04164732","source":"Novartis","relevant":null},{"trial_id":276,"title":"Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis","summary":"","published_date":"2021-10-08T16:09:38Z","discovery_date":"2021-10-08T16:09:38Z","link":"https://www.novartis.com/clinicaltrials/study/nct04396366","source":"Novartis","relevant":null},{"trial_id":273,"title":"Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD","summary":"","published_date":"2021-10-08T16:09:38Z","discovery_date":"2021-10-08T16:09:38Z","link":"https://www.novartis.com/clinicaltrials/study/nct04882124","source":"Novartis","relevant":null},{"trial_id":274,"title":"Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D","summary":"","published_date":"2021-10-08T16:09:38Z","discovery_date":"2021-10-08T16:09:38Z","link":"https://www.novartis.com/clinicaltrials/study/nct04491136","source":"Novartis","relevant":null},{"trial_id":272,"title":"Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","summary":"","published_date":"2021-10-08T16:09:38Z","discovery_date":"2021-10-08T16:09:38Z","link":"https://www.novartis.com/clinicaltrials/study/nct04390763","source":"Novartis","relevant":null},{"trial_id":271,"title":"Lifestyle Weight Management Program: Interviews and Stakeholder Meetings.","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Paediatric Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Observational Study.&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Oxford Brookes University;   Great Ormond Street Hospital for Children NHS Foundation Trust;   Guy&#39;s and St Thomas&#39; NHS Foundation Trust;   Oxford University Hospitals NHS Trust&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-07T16:00:00Z","discovery_date":"2021-10-07T12:16:14Z","link":"https://clinicaltrials.gov/ct2/show/NCT05070286?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":270,"title":"Neuromuscular Electrostimulation in Multiple Sclerosis People With Dysphagia","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Deglutition Disorders;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation;   Device: Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulation&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    I.R.C.C.S. Fondazione Santa Lucia&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-01T16:00:00Z","discovery_date":"2021-10-01T10:56:35Z","link":"https://clinicaltrials.gov/ct2/show/NCT05063708?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":269,"title":"A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: 11C-BMS-986196&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Bristol-Myers Squibb&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-10-01T16:00:00Z","discovery_date":"2021-10-01T10:56:35Z","link":"https://clinicaltrials.gov/ct2/show/NCT05064436?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":268,"title":"PET Imaging of Cyclooxygenase-2 in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: 11C-MCI&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    National Institute of Mental Health (NIMH);   University of Maryland, College Park&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-30T16:00:00Z","discovery_date":"2021-09-30T22:16:35Z","link":"https://clinicaltrials.gov/ct2/show/NCT05062083?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":267,"title":"Development and Validation of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: Eye-Tracking&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Innodem Neurosciences&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-30T16:00:00Z","discovery_date":"2021-09-30T22:16:35Z","link":"https://clinicaltrials.gov/ct2/show/NCT05061953?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":266,"title":"COVID Vaccine Response in MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Healthy&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Blood draw&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Brigham and Women&#39;s Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-29T16:00:00Z","discovery_date":"2021-09-29T11:39:07Z","link":"https://clinicaltrials.gov/ct2/show/NCT05060354?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":265,"title":"MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Biogen&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-28T16:00:00Z","discovery_date":"2021-09-28T13:29:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05058729?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":264,"title":"Autoimmune Intervention Mastery Course Study","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Clinically Isolated Syndrome&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Immediate Autoimmune Intervention Mastery Course;   Behavioral: Immediate Question and Answer sessions.;   Behavioral: Delayed Autoimmune Intervention Mastery Course;   Behavioral: Delayed Question and Answer sessions&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Terry L. Wahls&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-27T16:00:00Z","discovery_date":"2021-09-27T11:53:46Z","link":"https://clinicaltrials.gov/ct2/show/NCT05057676?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":263,"title":"Functions, Physical Activity and Employment for Individuals With MS: A Pilot Feasibility Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: CoreDISTparticipation;   Behavioral: Standard care&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Nordlandssykehuset HF;   Nord University;   Hasselt University;   Helse Nord&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","published_date":"2021-09-27T16:00:00Z","discovery_date":"2021-09-27T11:53:46Z","link":"https://clinicaltrials.gov/ct2/show/NCT05057338?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":261,"title":"Ultrasound-Guided Percutaneous Neuromodulation in Spasticity","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Procedure: Percutaneous Echoguided Neuromodulation&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hospital Universitario de Canarias&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-23T16:00:00Z","discovery_date":"2021-09-23T17:49:58Z","link":"https://clinicaltrials.gov/ct2/show/NCT05053984?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":262,"title":"Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: IMU-838;   Drug: Placebo matching IMU-838&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Immunic AG&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-23T16:00:00Z","discovery_date":"2021-09-23T17:49:58Z","link":"https://clinicaltrials.gov/ct2/show/NCT05054140?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":260,"title":"Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Major Depressive Disorder&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: POWER-MS;   Behavioral: FLEX-MS&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Alabama at Birmingham;   Congressionally Directed Medical Research Programs&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-21T16:00:00Z","discovery_date":"2021-09-21T13:11:04Z","link":"https://clinicaltrials.gov/ct2/show/NCT05051618?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":259,"title":"A Long-term Extension of Study GNC-401","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Temelimab 18 mg&#x2F;kg;   Drug: Temelimab 36mg&#x2F;kg;   Drug: Temelimab 54 mg&#x2F;kg&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    GeNeuro Innovation SAS&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-17T16:00:00Z","discovery_date":"2021-09-17T15:00:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT05049161?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":258,"title":"The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Sleep quality and physical activity;   Genetic: Nicotine dependence;   Diagnostic Test: Nicotine and cotinine serum levels;   Behavioral: Smoking&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Jordan&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-16T16:00:00Z","discovery_date":"2021-09-16T16:50:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT05046535?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":257,"title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","summary":"","published_date":"2021-09-06T00:04:28Z","discovery_date":"2021-09-06T00:04:28Z","link":"https://www.novartis.com/clinicaltrials/study/nct04711135","source":"Novartis","relevant":null},{"trial_id":256,"title":"A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)","summary":"","published_date":"2021-09-06T00:04:27Z","discovery_date":"2021-09-06T00:04:27Z","link":"https://www.novartis.com/clinicaltrials/study/nct04814368","source":"Novartis","relevant":null},{"trial_id":255,"title":"Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: questionnaire&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Assistance Publique - Hôpitaux de Paris&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-03T16:00:00Z","discovery_date":"2021-09-05T16:31:06Z","link":"https://clinicaltrials.gov/ct2/show/NCT05033782?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":251,"title":"Special Drug Use-results Surveillance of Tabrecta Tablets","summary":"","published_date":"2021-09-02T23:31:19Z","discovery_date":"2021-09-02T23:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct04575025","source":"Novartis","relevant":null},{"trial_id":254,"title":"Dabrafenib and&#x2F;or Trametinib Rollover Study","summary":"","published_date":"2021-09-02T23:31:19Z","discovery_date":"2021-09-02T23:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct03340506","source":"Novartis","relevant":null},{"trial_id":253,"title":"Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis","summary":"","published_date":"2021-09-02T23:31:19Z","discovery_date":"2021-09-02T23:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct04074590","source":"Novartis","relevant":null},{"trial_id":252,"title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","summary":"","published_date":"2021-09-02T23:31:19Z","discovery_date":"2021-09-02T23:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct03839823","source":"Novartis","relevant":null},{"trial_id":250,"title":"The Gilenya Pregnancy Registry","summary":"","published_date":"2021-09-02T23:31:19Z","discovery_date":"2021-09-02T23:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct01285479","source":"Novartis","relevant":null},{"trial_id":249,"title":"Development and Application of Tele-Neuro Rehabilitation System","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Stroke;   Multiple Sclerosis;   Parkinson Disease&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Telerehabilitaton;   Other: Home Exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Istanbul University-Cerrahpasa;   The Scientific and Technological Research Council of Turkey&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-01T16:00:00Z","discovery_date":"2021-09-01T16:27:57Z","link":"https://clinicaltrials.gov/ct2/show/NCT05031403?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":248,"title":"Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis Acute and Progressive&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Combination Product: investigations like MRI..&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Assiut University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-09-01T16:00:00Z","discovery_date":"2021-09-01T16:27:57Z","link":"https://clinicaltrials.gov/ct2/show/NCT05029830?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":245,"title":"Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","summary":"","published_date":"2021-09-01T02:31:19Z","discovery_date":"2021-09-01T02:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct04524442","source":"Novartis","relevant":null},{"trial_id":247,"title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","summary":"","published_date":"2021-09-01T02:31:19Z","discovery_date":"2021-09-01T02:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct04597411","source":"Novartis","relevant":null},{"trial_id":246,"title":"A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD","summary":"","published_date":"2021-09-01T02:31:19Z","discovery_date":"2021-09-01T02:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct04632056","source":"Novartis","relevant":null},{"trial_id":244,"title":"[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake","summary":"","published_date":"2021-09-01T02:31:19Z","discovery_date":"2021-09-01T02:31:19Z","link":"https://www.novartis.com/clinicaltrials/study/nct03872778","source":"Novartis","relevant":null},{"trial_id":243,"title":"Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Intranasal Foralumab Solution;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Tiziana Life Sciences, PLC&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-31T16:00:00Z","discovery_date":"2021-08-31T15:55:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05029609?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":241,"title":"The Effects of Trunk Stabilization and Aerobic Trainings in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Physical Therapy&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Combined exercise training;   Other: Aerobic training&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Ankara Yildirim Beyazıt University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-08-31T16:00:00Z","discovery_date":"2021-08-31T15:55:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05029700?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":242,"title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Procedure: Autologous hematopoietic stem cell transplantation&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Uppsala University;   Karolinska University Hospital;   Sahlgrenska University Hospital, Sweden;   Uppsala University Hospital;   Skane University Hospital;   University Hospital, Linkoeping;   University Hospital, Umeå;   Region Örebro County&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-31T16:00:00Z","discovery_date":"2021-08-31T15:55:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT05029206?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":240,"title":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Tetanus, diphtheria, and acellular pertussis vaccine;   Biological: Pneumococcal polysaccharide vaccine;   Biological: Seasonal influenza vaccine&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Celgene&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-31T16:00:00Z","discovery_date":"2021-08-31T15:55:07Z","link":"https://clinicaltrials.gov/ct2/show/NCT05028634?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":238,"title":"Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)","summary":"","published_date":"2021-08-31T02:48:29Z","discovery_date":"2021-08-31T02:48:29Z","link":"https://www.novartis.com/clinicaltrials/study/nct04630158","source":"Novartis","relevant":null},{"trial_id":239,"title":"An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients","summary":"","published_date":"2021-08-31T02:48:29Z","discovery_date":"2021-08-31T02:48:29Z","link":"https://www.novartis.com/clinicaltrials/study/nct04662931","source":"Novartis","relevant":null},{"trial_id":237,"title":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","summary":"","published_date":"2021-08-27T18:48:30Z","discovery_date":"2021-08-27T18:48:30Z","link":"https://www.novartis.com/clinicaltrials/study/nct04662944","source":"Novartis","relevant":null},{"trial_id":236,"title":"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer&#39;s Type.","summary":"","published_date":"2021-08-27T18:48:30Z","discovery_date":"2021-08-27T18:48:30Z","link":"https://www.novartis.com/clinicaltrials/study/nct02989402","source":"Novartis","relevant":null},{"trial_id":235,"title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","summary":"","published_date":"2021-08-27T18:48:30Z","discovery_date":"2021-08-27T18:48:30Z","link":"https://www.novartis.com/clinicaltrials/study/nct03972488","source":"Novartis","relevant":null},{"trial_id":232,"title":"Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients","summary":"","published_date":"2021-08-26T20:34:56Z","discovery_date":"2021-08-26T20:34:56Z","link":"https://www.novartis.com/clinicaltrials/study/nct04593927","source":"Novartis","relevant":null},{"trial_id":234,"title":"Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.","summary":"","published_date":"2021-08-26T20:34:56Z","discovery_date":"2021-08-26T20:34:56Z","link":"https://www.novartis.com/clinicaltrials/study/nct04712721","source":"Novartis","relevant":null},{"trial_id":233,"title":"Special Drug Use Surveillance for Entresto Tablets","summary":"","published_date":"2021-08-26T20:34:56Z","discovery_date":"2021-08-26T20:34:56Z","link":"https://www.novartis.com/clinicaltrials/study/nct04781881","source":"Novartis","relevant":null},{"trial_id":228,"title":"Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma","summary":"","published_date":"2021-08-26T00:47:17Z","discovery_date":"2021-08-26T00:47:17Z","link":"https://www.novartis.com/clinicaltrials/study/nct04410523","source":"Novartis","relevant":null},{"trial_id":230,"title":"Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients","summary":"","published_date":"2021-08-26T00:47:17Z","discovery_date":"2021-08-26T00:47:17Z","link":"https://www.novartis.com/clinicaltrials/study/nct03814746","source":"Novartis","relevant":null},{"trial_id":229,"title":"Study to Evaluate the Efficacy and Safety of MAS825 in NLRC4-GOF Patients","summary":"","published_date":"2021-08-26T00:47:17Z","discovery_date":"2021-08-26T00:47:17Z","link":"https://www.novartis.com/clinicaltrials/study/nct04641442","source":"Novartis","relevant":null},{"trial_id":227,"title":"A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.","summary":"","published_date":"2021-08-24T18:47:17Z","discovery_date":"2021-08-24T18:47:17Z","link":"https://www.novartis.com/clinicaltrials/study/nct04836858","source":"Novartis","relevant":null},{"trial_id":225,"title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC","summary":"","published_date":"2021-08-24T18:47:16Z","discovery_date":"2021-08-24T18:47:16Z","link":"https://www.novartis.com/clinicaltrials/study/nct04720157","source":"Novartis","relevant":null},{"trial_id":224,"title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","summary":"","published_date":"2021-08-24T18:47:16Z","discovery_date":"2021-08-24T18:47:16Z","link":"https://www.novartis.com/clinicaltrials/study/nct03798626","source":"Novartis","relevant":null},{"trial_id":226,"title":"Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum","summary":"","published_date":"2021-08-24T18:47:16Z","discovery_date":"2021-08-24T18:47:16Z","link":"https://www.novartis.com/clinicaltrials/study/nct04589650","source":"Novartis","relevant":null},{"trial_id":223,"title":"Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Vaccine Response Impaired&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: Most recent vaccine to seasonal influenza&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Heinrich-Heine University, Duesseldorf&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-24T16:00:00Z","discovery_date":"2021-08-24T13:43:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05019248?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":221,"title":"A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.","summary":"","published_date":"2021-08-23T17:47:17Z","discovery_date":"2021-08-23T17:47:17Z","link":"https://www.novartis.com/clinicaltrials/study/nct04806503","source":"Novartis","relevant":null},{"trial_id":219,"title":"The Role of Social and Territorial Inequalities in the Management and Prognosis of Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Social and Territorial Inequalities&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Central Hospital, Nancy, France&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-23T16:00:00Z","discovery_date":"2021-08-23T12:23:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05017038?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":220,"title":"Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Optic Neuritis;   Transverse Myelitis;   Acute Disseminated Encephalomyelitis;   Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorder;   Anti-NMDAR Encephalitis;   Anti-GAD65 Associated Autoimmune Encephalitis;   Anti-AMPAR-1&#x2F;2 Associated Autoimmune Encephalitis;   Anti-Lgi-1 Associated Autoimmune Encephalitis;   Anti-CASPR-2 Associated Autoimmune Encephalitis;   Anti-GABAR-1&#x2F;2 Associated Autoimmune Encephalitis;   Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis;   Hashimoto Encephalitis;   CNS Vasculitis;   CNS Sarcoidosis;   CNS Lupus;   Rasmussen Encephalitis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Bern;   Schweizerische Multiple Sklerose Gesellschaft;   University Hospital Inselspital, Berne;   Roche Pharma (Switzerland) Ltd;   Novartis&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-23T16:00:00Z","discovery_date":"2021-08-23T12:23:55Z","link":"https://clinicaltrials.gov/ct2/show/NCT05017142?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":217,"title":"Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions","summary":"","published_date":"2021-08-19T22:19:09Z","discovery_date":"2021-08-19T22:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04656223","source":"Novartis","relevant":null},{"trial_id":218,"title":"Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.","summary":"","published_date":"2021-08-19T22:19:09Z","discovery_date":"2021-08-19T22:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04711902","source":"Novartis","relevant":null},{"trial_id":216,"title":"Hydroxychloroquine and Indapamide in SPMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Secondary Progressive&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Hydroxychloroquine and Indapamide&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Calgary&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-19T16:00:00Z","discovery_date":"2021-08-19T15:05:47Z","link":"https://clinicaltrials.gov/ct2/show/NCT05013463?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":215,"title":"The Reliability of the Nine Hole Peg Test in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Motor Activity&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Nine Hole Peg Test&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Charles University, Czech Republic&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-19T16:00:00Z","discovery_date":"2021-08-19T15:05:47Z","link":"https://clinicaltrials.gov/ct2/show/NCT05012241?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":210,"title":"Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis","summary":"","published_date":"2021-08-19T12:19:09Z","discovery_date":"2021-08-19T12:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04864392","source":"Novartis","relevant":null},{"trial_id":211,"title":"Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration","summary":"","published_date":"2021-08-19T12:19:09Z","discovery_date":"2021-08-19T12:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04679935","source":"Novartis","relevant":null},{"trial_id":213,"title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","summary":"","published_date":"2021-08-19T12:19:09Z","discovery_date":"2021-08-19T12:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct03570892","source":"Novartis","relevant":null},{"trial_id":214,"title":"A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","summary":"","published_date":"2021-08-19T12:19:09Z","discovery_date":"2021-08-19T12:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04667117","source":"Novartis","relevant":null},{"trial_id":201,"title":"Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis","summary":"","published_date":"2021-08-19T02:19:10Z","discovery_date":"2021-08-19T02:19:10Z","link":"https://www.novartis.com/clinicaltrials/study/nct04732117","source":"Novartis","relevant":null},{"trial_id":202,"title":"Efficacy, Safety and Tolerability of the Combination of Tropifexor &amp; Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.","summary":"","published_date":"2021-08-19T02:19:10Z","discovery_date":"2021-08-19T02:19:10Z","link":"https://www.novartis.com/clinicaltrials/study/nct04065841","source":"Novartis","relevant":null},{"trial_id":203,"title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up","summary":"","published_date":"2021-08-19T02:19:10Z","discovery_date":"2021-08-19T02:19:10Z","link":"https://www.novartis.com/clinicaltrials/study/nct03781414","source":"Novartis","relevant":null},{"trial_id":205,"title":"Study of Out of Specification for Tisagenlecleucel","summary":"","published_date":"2021-08-19T02:19:10Z","discovery_date":"2021-08-19T02:19:10Z","link":"https://www.novartis.com/clinicaltrials/study/nct04094311","source":"Novartis","relevant":null},{"trial_id":207,"title":"Secukinumab Open Label Roll-over Extension Protocol","summary":"","published_date":"2021-08-19T02:19:10Z","discovery_date":"2021-08-19T02:19:10Z","link":"https://www.novartis.com/clinicaltrials/study/nct04638647","source":"Novartis","relevant":null},{"trial_id":200,"title":"A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism","summary":"","published_date":"2021-08-19T02:19:10Z","discovery_date":"2021-08-19T02:19:10Z","link":"https://www.novartis.com/clinicaltrials/study/nct03938454","source":"Novartis","relevant":null},{"trial_id":206,"title":"Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa","summary":"","published_date":"2021-08-19T02:19:10Z","discovery_date":"2021-08-19T02:19:10Z","link":"https://www.novartis.com/clinicaltrials/study/nct04179175","source":"Novartis","relevant":null},{"trial_id":208,"title":"Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab","summary":"","published_date":"2021-08-19T02:19:10Z","discovery_date":"2021-08-19T02:19:10Z","link":"https://www.novartis.com/clinicaltrials/study/nct04210843","source":"Novartis","relevant":null},{"trial_id":199,"title":"Pregnancy Cohort in Multiple Sclerosis (MS)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS);   Clinically Isolated Syndrome (CIS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Charite University, Berlin, Germany&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-18T16:00:00Z","discovery_date":"2021-08-18T13:45:47Z","link":"https://clinicaltrials.gov/ct2/show/NCT05010902?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":198,"title":"Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy","summary":"","published_date":"2021-08-17T20:19:09Z","discovery_date":"2021-08-17T20:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04278417","source":"Novartis","relevant":null},{"trial_id":195,"title":"DreaMS - Validation Study 1","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: dreaMS App R2.0&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Research Center for Clinical Neuroimmunology and Neuroscience Basel;   Healios AG;   University Hospital, Basel, Switzerland;   University of Basel;   Innosuisse - Swiss Innovation Agency;   Novartis Pharmaceuticals;   Hoffmann-La Roche&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-17T16:00:00Z","discovery_date":"2021-08-17T15:35:47Z","link":"https://clinicaltrials.gov/ct2/show/NCT05009160?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":193,"title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","summary":"","published_date":"2021-08-17T00:19:09Z","discovery_date":"2021-08-17T00:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04251533","source":"Novartis","relevant":null},{"trial_id":194,"title":"Alpelisib Plus Olaparib in Platinum-resistant&#x2F;Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","summary":"","published_date":"2021-08-17T00:19:09Z","discovery_date":"2021-08-17T00:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04729387","source":"Novartis","relevant":null},{"trial_id":192,"title":"Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)","summary":"","published_date":"2021-08-17T00:19:09Z","discovery_date":"2021-08-17T00:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04174157","source":"Novartis","relevant":null},{"trial_id":191,"title":"Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren&#39;s Syndrome","summary":"","published_date":"2021-08-17T00:19:09Z","discovery_date":"2021-08-17T00:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct03905525","source":"Novartis","relevant":null},{"trial_id":190,"title":"Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration","summary":"","published_date":"2021-08-17T00:19:09Z","discovery_date":"2021-08-17T00:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct04864834","source":"Novartis","relevant":null},{"trial_id":189,"title":"Efficacy of Diet on Quality of Life in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Dietary Supplement: BodyBio Balance Oil;   Dietary Supplement: Kirunal Fish Oil;   Dietary Supplement: BodyBio PC;   Behavioral: Modified Paleolithic Elimination diet;   Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet;   Behavioral: Dietary Guidelines for Americans Diet&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Terry L. Wahls&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-16T16:00:00Z","discovery_date":"2021-08-16T17:25:47Z","link":"https://clinicaltrials.gov/ct2/show/NCT05007483?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":187,"title":"A Teleheath tDCS Approach to Decrease Cannabis Use","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Cannabis Use Disorder;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Transcranial Direct Current Stimulation (tDCS);   Other: Sham - Transcranial Direct Current Stimulation (tDCS);   Other: Mindfulness&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    NYU Langone Health&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-13T16:00:00Z","discovery_date":"2021-08-13T13:25:47Z","link":"https://clinicaltrials.gov/ct2/show/NCT05005013?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":185,"title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","summary":"","published_date":"2021-08-12T20:19:09Z","discovery_date":"2021-08-12T20:19:09Z","link":"https://www.novartis.com/clinicaltrials/study/nct03650114","source":"Novartis","relevant":null},{"trial_id":181,"title":"An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab","summary":"","published_date":"2021-08-12T15:19:08Z","discovery_date":"2021-08-12T15:19:08Z","link":"https://www.novartis.com/clinicaltrials/study/nct04353492","source":"Novartis","relevant":null},{"trial_id":182,"title":"Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis","summary":"","published_date":"2021-08-12T15:19:08Z","discovery_date":"2021-08-12T15:19:08Z","link":"https://www.novartis.com/clinicaltrials/study/nct01892722","source":"Novartis","relevant":null},{"trial_id":184,"title":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","summary":"","published_date":"2021-08-12T15:19:08Z","discovery_date":"2021-08-12T15:19:08Z","link":"https://www.novartis.com/clinicaltrials/study/nct04544189","source":"Novartis","relevant":null},{"trial_id":176,"title":"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis","summary":"","published_date":"2021-08-12T15:09:11Z","discovery_date":"2021-08-12T15:09:11Z","link":"https://www.novartis.com/clinicaltrials/study/nct04486716","source":"Novartis","relevant":null},{"trial_id":178,"title":"Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.","summary":"","published_date":"2021-08-12T15:09:11Z","discovery_date":"2021-08-12T15:09:11Z","link":"https://www.novartis.com/clinicaltrials/study/nct04623216","source":"Novartis","relevant":null},{"trial_id":175,"title":"Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","summary":"","published_date":"2021-08-12T15:09:11Z","discovery_date":"2021-08-12T15:09:11Z","link":"https://www.novartis.com/clinicaltrials/study/nct04666259","source":"Novartis","relevant":null},{"trial_id":172,"title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy","summary":"","published_date":"2021-08-12T15:09:11Z","discovery_date":"2021-08-12T15:09:11Z","link":"https://www.novartis.com/clinicaltrials/study/nct04539041","source":"Novartis","relevant":null},{"trial_id":180,"title":"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients.","summary":"","published_date":"2021-08-12T15:09:11Z","discovery_date":"2021-08-12T15:09:11Z","link":"https://www.novartis.com/clinicaltrials/study/nct03623243","source":"Novartis","relevant":null},{"trial_id":179,"title":"Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients","summary":"","published_date":"2021-08-12T15:09:11Z","discovery_date":"2021-08-12T15:09:11Z","link":"https://www.novartis.com/clinicaltrials/study/nct04667949","source":"Novartis","relevant":null},{"trial_id":177,"title":"A Randomized Study to Evaluate the Effect of an &quot;Inclisiran First&quot; Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)","summary":"","published_date":"2021-08-12T15:09:11Z","discovery_date":"2021-08-12T15:09:11Z","link":"https://www.novartis.com/clinicaltrials/study/nct04929249","source":"Novartis","relevant":null},{"trial_id":170,"title":"Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Fatigue;   Stress&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: High-challenging cognitive protocol to provoke stress and (cognitive) fatigue&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    KU Leuven;   National MS Center Melsbroek&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-12T16:00:00Z","discovery_date":"2021-08-12T13:29:25Z","link":"https://clinicaltrials.gov/ct2/show/NCT05003375?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":169,"title":"Efficacy of Cognitive Behavioral Therapy on Fatigue, Cognition and Inflammatory Biomarkers in MS Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: &quot;RehaCom&quot; computer-based cognitive training in addition to Conventional physical therapy program;   Other: Conventional physical therapy program&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Cairo University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-08-12T16:00:00Z","discovery_date":"2021-08-12T13:29:25Z","link":"https://clinicaltrials.gov/ct2/show/NCT05002062?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":168,"title":"Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: AlloRx&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    The Foundation for Orthopaedics and Regenerative Medicine&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-12T16:00:00Z","discovery_date":"2021-08-12T13:29:25Z","link":"https://clinicaltrials.gov/ct2/show/NCT05003388?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":167,"title":"Thalamic Nuclei Volumes in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Bordeaux;   Institut National de la Santé Et de la Recherche Médicale, France&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-12T16:00:00Z","discovery_date":"2021-08-12T13:29:25Z","link":"https://clinicaltrials.gov/ct2/show/NCT05002764?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":166,"title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Rheumatoid Arthritis;   Systemic Lupus Erythematosus (SLE);   Pemphigus Vulgaris;   Multiple Sclerosis;   Systemic Sclerosis (SSc)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Moderna mRNA-1273;   Biological: BNT162b2;   Biological: Ad26.COV2.S;   Drug: IS (MMF or MPA);   Drug: IS (MTX);   Biological: IS (B cell depletion therapy)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence;   Rho Federal Systems Division, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-11T16:00:00Z","discovery_date":"2021-08-11T15:21:39Z","link":"https://clinicaltrials.gov/ct2/show/NCT05000216?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":164,"title":"A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Clinically Isolated Syndrome&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hoffmann-La Roche;   PPD;   LabCorp;   Illingworth&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-10T16:00:00Z","discovery_date":"2021-08-10T14:01:41Z","link":"https://clinicaltrials.gov/ct2/show/NCT04998851?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":165,"title":"A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Clinically Isolated Syndrome&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hoffmann-La Roche;   PPD;   LabCorp;   Illingworth&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-10T16:00:00Z","discovery_date":"2021-08-10T14:01:41Z","link":"https://clinicaltrials.gov/ct2/show/NCT04998812?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":162,"title":"Neurophysiological Assessment in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Demyelinating Disease;   Inflammatory Disease&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Neurophysiological assessment;   Other: clinical assessment&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Roma La Sapienza&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-09T16:00:00Z","discovery_date":"2021-08-09T12:36:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04997343?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":163,"title":"Symptoms and Treatment Assessment of Ano-Rectal Disorders in Multiple Sclerosis Patients : STAR-Q","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Constipation;   Fecal Incontinence&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Clinical interviews&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Pierre and Marie Curie University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-08-09T16:00:00Z","discovery_date":"2021-08-09T12:36:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04996186?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":161,"title":"Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing-Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck Serono Limited, an affiliate of Merck KGaA, Darmstadt, Germany&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-09T16:00:00Z","discovery_date":"2021-08-09T12:36:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04997148?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":159,"title":"Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)","summary":"","published_date":"2021-08-07T00:23:03Z","discovery_date":"2021-08-07T00:23:03Z","link":"https://www.novartis.com/clinicaltrials/study/nct04443907","source":"Novartis","relevant":null},{"trial_id":160,"title":"Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment","summary":"","published_date":"2021-08-07T00:23:03Z","discovery_date":"2021-08-07T00:23:03Z","link":"https://www.novartis.com/clinicaltrials/study/nct04587622","source":"Novartis","relevant":null},{"trial_id":157,"title":"Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Magnetic Resonance Imaging&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: T1rho imaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Chinese University of Hong Kong&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-06T16:00:00Z","discovery_date":"2021-08-06T12:10:36Z","link":"https://clinicaltrials.gov/ct2/show/NCT04993196?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":158,"title":"Sensitivity of Motor Assessment in MS - a Prospective Cohort Study","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Chronic Progressive&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: PASS-MS&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Friedemann Paul;   Roche Pharma AG&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-06T16:00:00Z","discovery_date":"2021-08-06T12:10:36Z","link":"https://clinicaltrials.gov/ct2/show/NCT04993274?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":153,"title":"Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis","summary":"","published_date":"2021-08-05T22:46:35Z","discovery_date":"2021-08-05T22:46:35Z","link":"https://www.novartis.com/clinicaltrials/study/nct04064242","source":"Novartis","relevant":null},{"trial_id":151,"title":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","summary":"","published_date":"2021-08-05T22:46:35Z","discovery_date":"2021-08-05T22:46:35Z","link":"https://www.novartis.com/clinicaltrials/study/nct03876769","source":"Novartis","relevant":null},{"trial_id":156,"title":"Study of Safety and of the Mechanism of BLZ945 in ALS Patients","summary":"","published_date":"2021-08-05T22:46:35Z","discovery_date":"2021-08-05T22:46:35Z","link":"https://www.novartis.com/clinicaltrials/study/nct04066244","source":"Novartis","relevant":null},{"trial_id":154,"title":"Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent","summary":"","published_date":"2021-08-05T22:46:35Z","discovery_date":"2021-08-05T22:46:35Z","link":"https://www.novartis.com/clinicaltrials/study/nct04722666","source":"Novartis","relevant":null},{"trial_id":155,"title":"Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to &lt; 12 Years Old With Asthma","summary":"","published_date":"2021-08-05T22:46:35Z","discovery_date":"2021-08-05T22:46:35Z","link":"https://www.novartis.com/clinicaltrials/study/nct04589663","source":"Novartis","relevant":null},{"trial_id":150,"title":"Pronesimod no tratamento de Esclerose Múltipla Recidivante | CUF","summary":"","published_date":"2021-08-05T15:59:12Z","discovery_date":"2021-08-05T15:59:12Z","link":"https://www.cuf.pt/cuf-academic-center/ensaios-clinicos/pronesimod-no-tratamento-de-esclerose-multipla-recidivante","source":"CUF","relevant":null},{"trial_id":149,"title":"177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","summary":"","published_date":"2021-08-05T15:53:54Z","discovery_date":"2021-08-05T15:53:54Z","link":"https://www.novartis.com/clinicaltrials/study/nct04689828","source":"Novartis","relevant":null},{"trial_id":137,"title":"Home","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com/","source":"Novartis","relevant":null},{"trial_id":148,"title":"Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct04578834","source":"Novartis","relevant":null},{"trial_id":146,"title":"Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct04868968","source":"Novartis","relevant":null},{"trial_id":145,"title":"Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct04072887","source":"Novartis","relevant":null},{"trial_id":144,"title":"Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct04023552","source":"Novartis","relevant":null},{"trial_id":147,"title":"Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct02859727","source":"Novartis","relevant":null},{"trial_id":143,"title":"A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct04582409","source":"Novartis","relevant":null},{"trial_id":142,"title":"Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct04873934","source":"Novartis","relevant":null},{"trial_id":141,"title":"Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct04558918","source":"Novartis","relevant":null},{"trial_id":139,"title":"Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia","summary":"","published_date":"2021-08-05T15:39:00Z","discovery_date":"2021-08-05T15:39:00Z","link":"https://www.novartis.com//clinicaltrials/study/nct04652726","source":"Novartis","relevant":null},{"trial_id":136,"title":"Territorial Implementation and Evaluation of a Multiple Sclerosis Expert Patient Program","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Quality of Life;   Patient Empowerment;   Patient Activation;   Fatigue;   Peer Group&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Multiple Sclerosis Expert Patient Program of Catalonia&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hospital Universitari Vall d&#39;Hebron Research Institute;   Strategic Plan for Research and Innovation in Health (ref. BDNS 542793)&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-04T16:00:00Z","discovery_date":"2021-08-04T13:22:57Z","link":"https://clinicaltrials.gov/ct2/show/NCT04988880?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":135,"title":"A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Lu AG06466;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    H. Lundbeck A&#x2F;S&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-08-04T16:00:00Z","discovery_date":"2021-08-04T13:22:57Z","link":"https://clinicaltrials.gov/ct2/show/NCT04990219?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":134,"title":"Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Spasticity With Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Nabiximols;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    GW Pharmaceuticals Ltd.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-30T16:00:00Z","discovery_date":"2021-07-30T17:01:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04984278?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":133,"title":"Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis Healthy Subjects&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: RIPK1 inhibitor&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sanofi&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-29T16:00:00Z","discovery_date":"2021-07-29T14:28:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04982991?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":130,"title":"Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Anxiety;   Depression;   Patient Satisfaction&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist;   Other: Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Alberta;   University Hospital Foundation&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-28T16:00:00Z","discovery_date":"2021-07-28T18:48:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04979546?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":129,"title":"The Validity and Reliability of the Upper Extremity Exercise Testing (UULEX) in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Upper extremity endurance test (UULEX)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Marmara University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-28T16:00:00Z","discovery_date":"2021-07-28T18:48:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04979819?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":132,"title":"Telerehabilitation in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Telerehabilitation;   Other: Video exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Marmara University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-28T16:00:00Z","discovery_date":"2021-07-28T18:48:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04979845?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":131,"title":"Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Magnetic Resonance Imaging;   Methylprednisolone&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Methylprednisolone succinate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Mazandaran University of Medical Sciences&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","published_date":"2021-07-28T16:00:00Z","discovery_date":"2021-07-28T18:48:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04979650?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":128,"title":"Gray Matter Demyelination in Primary Progressive MS at 7T","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Primary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Danish Research Centre for Magnetic Resonance;   Scleroseforeningen;   Danish Multiple Sclerosis Center&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-27T16:00:00Z","discovery_date":"2021-07-27T15:16:12Z","link":"https://clinicaltrials.gov/ct2/show/NCT04977622?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":127,"title":"Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: SMART;   Behavioral: Sham brain training (Sudoku)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Lincoln;   University of Exeter;   Nottinghamshire Healthcare NHS Trust;   National University of Ireland, Maynooth;   University of Nottingham&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-23T16:00:00Z","discovery_date":"2021-07-23T12:56:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04975685?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":125,"title":"Functional Disorders of the Musculoskeletal System in People With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Rehabilitation;   Musculoskeletal Complication&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Manual physiotherapeutic correction (MFK) Method;   Behavioral: Dynamic Neuromuscular Stabilization (DNS) Method&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Charles University, Czech Republic&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-07-22T16:00:00Z","discovery_date":"2021-07-22T17:03:44Z","link":"https://clinicaltrials.gov/ct2/show/NCT04973501?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":126,"title":"Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Spinal Manipulation;   Other: Sham Spinal Manipulation&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Alabama at Birmingham&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-22T16:00:00Z","discovery_date":"2021-07-22T17:03:44Z","link":"https://clinicaltrials.gov/ct2/show/NCT04972929?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":123,"title":"Quantifying Gait Alteration in Multiple Sclerosis Using a Wearable Device","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Wearable sensor&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Nantes University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-21T16:00:00Z","discovery_date":"2021-07-21T12:32:44Z","link":"https://clinicaltrials.gov/ct2/show/NCT04969848?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":124,"title":"Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing-Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Ocrelizumab;   Drug: Alemtuzumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Universitätsklinikum Hamburg-Eppendorf;   Neovii Biotech;   Clinical Trial Center North (CTC North GmbH &amp; Co. KG)&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-21T16:00:00Z","discovery_date":"2021-07-21T12:32:44Z","link":"https://clinicaltrials.gov/ct2/show/NCT04971005?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":122,"title":"The Effect of Emotional Freedom Technique on Depression, Anxiety and Distress of Individuals With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Anxiety;   Depressive Symptoms;   Distress;   Psychiatric Nursing&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Emotional Freedom Technique&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Dokuz Eylul University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-20T16:00:00Z","discovery_date":"2021-07-20T13:49:06Z","link":"https://clinicaltrials.gov/ct2/show/NCT04969562?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":121,"title":"Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Ocrelizumab (CinnaGen, Iran);   Biological: Ocrelizumab (Roche, Switzerland)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Cinnagen&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-19T16:00:00Z","discovery_date":"2021-07-19T12:15:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT04966338?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":118,"title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton&#39;s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: SAR442168&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Peking University Third Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-16T16:00:00Z","discovery_date":"2021-07-16T13:27:06Z","link":"https://clinicaltrials.gov/ct2/show/NCT04964791?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":120,"title":"An Observational Study to Investigate the Role of B Cells in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Analysis of B cells&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Oslo&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-16T16:00:00Z","discovery_date":"2021-07-16T13:27:06Z","link":"https://clinicaltrials.gov/ct2/show/NCT04964336?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":119,"title":"Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Natalizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Multiple Sclerosis Center of Northeastern New York&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-16T16:00:00Z","discovery_date":"2021-07-16T13:27:06Z","link":"https://clinicaltrials.gov/ct2/show/NCT04964700?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":117,"title":"Effects of a User-centered Exergame Training on Motor and Cognitive Functions in PwMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Exergame Training&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Eling DeBruin&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-15T16:00:00Z","discovery_date":"2021-07-15T12:52:04Z","link":"https://clinicaltrials.gov/ct2/show/NCT04963335?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":116,"title":"A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: IMS001&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    ImStem Biotechnology;   Rho, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-09T16:00:00Z","discovery_date":"2021-07-09T11:20:04Z","link":"https://clinicaltrials.gov/ct2/show/NCT04956744?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":115,"title":"Technology-assisted Conscientiousness Therapy for People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Conscientiousness Coach&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    State University of New York at Buffalo&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-08T16:00:00Z","discovery_date":"2021-07-08T14:32:36Z","link":"https://clinicaltrials.gov/ct2/show/NCT04953689?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":113,"title":"Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Kidney Transplant;   Extracorporeal Dialysis;   Myeloma;   Cancer;   Hematologic Malignancy;   Multiple Sclerosis;   Hypergammaglobulinemia;   Malignant Tumor;   Hiv;   Diabetes Type 2&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: Biological samples&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Centre Hospitalier Régional d&#39;Orléans&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-07T16:00:00Z","discovery_date":"2021-07-07T11:59:36Z","link":"https://clinicaltrials.gov/ct2/show/NCT04952766?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":114,"title":"Clinical Isolation Syndrome of Spinal Cord and Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Clinical Isolation Syndrome of Spinal Cord;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Peking University Third Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-07-07T16:00:00Z","discovery_date":"2021-07-07T11:59:36Z","link":"https://clinicaltrials.gov/ct2/show/NCT04952246?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":110,"title":"Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Primary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: DUOC-01&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Joanne Kurtzberg, MD&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-29T16:00:00Z","discovery_date":"2021-06-29T16:46:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT04943289?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":109,"title":"Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Exercise Intervention;   Neuro-Degenerative Disease&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Regular Exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Ege University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-06-29T16:00:00Z","discovery_date":"2021-06-29T16:46:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT04944251?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":112,"title":"CONNECT Trial of eSupport Online Health-coach Moderated Support Groups for Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: eSupport Health Weekly Group Sessions for PwMS&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    eSupport Health&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-29T16:00:00Z","discovery_date":"2021-06-29T16:46:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT04943887?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":111,"title":"Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: NeuBie&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Centura Health;   NeuFit - Neurological Fitness and Education&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-29T16:00:00Z","discovery_date":"2021-06-29T16:46:42Z","link":"https://clinicaltrials.gov/ct2/show/NCT04942938?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":108,"title":"PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: PIPE-307&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Pipeline Therapeutics, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-28T16:00:00Z","discovery_date":"2021-06-28T16:23:24Z","link":"https://clinicaltrials.gov/ct2/show/NCT04941781?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":107,"title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Relapsing-remitting Multiple Sclerosis;   Active Secondary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Kesimpta&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-25T16:00:00Z","discovery_date":"2021-06-25T20:40:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04940065?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":106,"title":"Reading Problems Associated With Central Nervous System (CNS) Pathologies.","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Injury Brain;   Eye Abnormalities;   Multiple Sclerosis;   Parkinson Disease;   Ataxia, Cerebellar&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: eye tracking&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA;   Hospital Clínico Universitario de Valladolid;   Hospital del Río Hortega&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","published_date":"2021-06-24T16:00:00Z","discovery_date":"2021-06-24T16:09:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04937725?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":105,"title":"The Effect of Self-Acupressure Application on Functional Composite and Quality of Life in Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Self-Acupressure&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Istanbul Sabahattin Zaim University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-23T16:00:00Z","discovery_date":"2021-06-23T16:33:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04936555?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":104,"title":"Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Cladribine&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck Hellas sa., Greece&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-22T16:00:00Z","discovery_date":"2021-06-22T14:45:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04934800?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":102,"title":"Tele-Assessment and Face-to-Face Evaluation of Functional Gait Assessment in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Istanbul University-Cerrahpasa&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-21T16:00:00Z","discovery_date":"2021-06-21T20:04:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04932616?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":103,"title":"Investigation of Hand Functions and Related Parameters in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Uğur OVACIK;   Istanbul University-Cerrahpasa&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-21T16:00:00Z","discovery_date":"2021-06-21T20:04:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04933110?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":101,"title":"Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Siponimod&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-21T16:00:00Z","discovery_date":"2021-06-21T20:04:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04933552?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":98,"title":"The Gut Microbiome in Adult Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    National MS Center Melsbroek&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-06-17T16:00:00Z","discovery_date":"2021-06-18T22:15:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04929145?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":100,"title":"Feasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Cognitive Impairment&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Intermittent theta burst stimulation (iTBS);   Other: Sham Intermittent theta burst stimulation (iTBS)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Nottingham&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-18T16:00:00Z","discovery_date":"2021-06-18T22:15:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04931953?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":99,"title":"Description of Adherence to the Main Preventive Health Campaigns of Persons With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: phone interview&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Siena&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-18T16:00:00Z","discovery_date":"2021-06-18T22:15:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04930380?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":97,"title":"Multiple Sclerosis and Voiding Symptoms: How to Assess?","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Lower Urinary Tract Symptoms;   Voiding Disorders&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: voiding phase evaluation&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Pierre and Marie Curie University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-06-16T16:00:00Z","discovery_date":"2021-06-16T18:08:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04928716?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":96,"title":"Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Glatiramer Acetate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Cinnagen&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-06-16T16:00:00Z","discovery_date":"2021-06-16T18:08:49Z","link":"https://clinicaltrials.gov/ct2/show/NCT04928313?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":95,"title":"Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Fingolimod;   Drug: Ofatumumab;   Drug: Siponimod;   Other: Fingolimod placebo;   Other: Siponimod placebo;   Other: Ofatumumab placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-15T16:00:00Z","discovery_date":"2021-06-15T16:34:48Z","link":"https://clinicaltrials.gov/ct2/show/NCT04926818?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":94,"title":"Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Secondary-progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Mayzent;   Drug: Ocrevus&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Robert Zivadinov, MD, PhD&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-14T16:00:00Z","discovery_date":"2021-06-14T17:57:48Z","link":"https://clinicaltrials.gov/ct2/show/NCT04925557?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":93,"title":"Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: monomethyl fumarate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Banner Life Sciences LLC&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-14T16:00:00Z","discovery_date":"2021-06-14T17:57:48Z","link":"https://clinicaltrials.gov/ct2/show/NCT04925778?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":92,"title":"EEG and TMS-based Biomarkers of ALS, MS and FTD","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Procedure: 128 electrode electroencephalography (EEG);   Procedure: Transcranial magnetic stimulation (TMS)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Dublin, Trinity College;   Motor Neurone Disease Association, UK;   Irish Research Council, IE;   Health Research Board, IE;   Research Motor Neurone, IE;   Thierry Latran Foundation, FR;   ALS Association, USA&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-08T16:00:00Z","discovery_date":"2021-06-08T15:45:00Z","link":"https://clinicaltrials.gov/ct2/show/NCT04918251?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":91,"title":"Motor Asymmetry in Progressive Multiple Sclerosis Patients","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Radiation: Magnetic Resonance Imaging;   Diagnostic Test: Neurological examination;   Diagnostic Test: Multiple Sclerosis Functional Composite;   Diagnostic Test: Physiotherapist examination&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Rennes University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-08T16:00:00Z","discovery_date":"2021-06-08T15:45:00Z","link":"https://clinicaltrials.gov/ct2/show/NCT04918225?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":90,"title":"Exercise Booster Sessions in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Combination Product: Systematic aerobic training;   Combination Product: Systematic resistance training;   Combination Product: Aerobic training booster sessions;   Combination Product: Resistance training booster sessions&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Aarhus;   Oxford Brookes University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-06-03T16:00:00Z","discovery_date":"2021-06-03T15:01:28Z","link":"https://clinicaltrials.gov/ct2/show/NCT04913012?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":89,"title":"A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Stroke&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Clinical Scapular protocol (ClinScaP);   Other: the prevalence of trunk, scapula and upper limb impairments.;   Other: the interaction between trunk, scapula and upper limb impairments.&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hasselt University;   Revalidatie &amp; MS Centrum Overpelt;   Ziekenhuis Oost-Limburg;   National MS Center Melsbroek;   Jessa Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-31T16:00:00Z","discovery_date":"2021-06-01T17:47:28Z","link":"https://clinicaltrials.gov/ct2/show/NCT04908891?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":87,"title":"Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Quality of Life&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Occupational Performance Coaching&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Queen&#39;s University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-31T16:00:00Z","discovery_date":"2021-06-01T17:47:28Z","link":"https://clinicaltrials.gov/ct2/show/NCT04908085?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":88,"title":"Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Forms of Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: EHP-101 25 mg OD;   Drug: EHP-101 25 mg BID;   Drug: EHP-101 50 mg OD;   Drug: EHP-101 50 mg BID&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Emerald Health Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-31T16:00:00Z","discovery_date":"2021-06-01T17:47:28Z","link":"https://clinicaltrials.gov/ct2/show/NCT04909502?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":85,"title":"Next-Gen MS: Feed-forward PRO Data for MS Research","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    EMD Serono Research &amp; Development Institute, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-28T16:00:00Z","discovery_date":"2021-05-28T12:44:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT04907305?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":84,"title":"The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Forced Aerobic Exercise (FE);   Behavioral: Voluntary Aerobic Exercise (VE)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    The Cleveland Clinic&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-28T16:00:00Z","discovery_date":"2021-05-28T12:44:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT04906057?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":86,"title":"Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Estimate the Number of Spinal Cord Lesions Detected With the 3D FGAPSIR Sequence That Were Not Detected With the 3D PSIR Sequence&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: MRI&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Fondation Ophtalmologique Adolphe de Rothschild&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","published_date":"2021-05-28T16:00:00Z","discovery_date":"2021-05-28T12:44:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT04906928?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":83,"title":"Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Spasticity, Muscle;   Pain&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: FlowOx™&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Otivio AS;   Haukeland University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-27T16:00:00Z","discovery_date":"2021-05-27T12:09:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT04904016?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":82,"title":"The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis Relapse&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    IRCCS National Neurological Institute &quot;C. Mondino&quot; Foundation&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-26T16:00:00Z","discovery_date":"2021-05-26T15:30:08Z","link":"https://clinicaltrials.gov/ct2/show/NCT04902690?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":81,"title":"Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Siponimod&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-20T16:00:00Z","discovery_date":"2021-05-20T11:40:26Z","link":"https://clinicaltrials.gov/ct2/show/NCT04895202?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":80,"title":"Adapting mHealth Technology to Improve Patient Activation","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Spinal Cord Injuries;   Stroke;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Fatigue self-management SMS intervention&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Washington University School of Medicine;   The Foundation for Barnes-Jewish Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-19T16:00:00Z","discovery_date":"2021-05-19T11:05:28Z","link":"https://clinicaltrials.gov/ct2/show/NCT04893590?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":79,"title":"Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: blood sample&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Medical University of Graz&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-19T16:00:00Z","discovery_date":"2021-05-19T11:05:27Z","link":"https://clinicaltrials.gov/ct2/show/NCT04892134?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":78,"title":"Investigation of the Effects of Technology Supported Different Physiotherapy Approaches on Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Technology Supported Task-Oriented Circuit Training;   Other: Home-based Telerehabilitation&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hacettepe University&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-18T16:00:00Z","discovery_date":"2021-05-18T10:30:26Z","link":"https://clinicaltrials.gov/ct2/show/NCT04891341?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":77,"title":"Holter of Movement in Patients With Multiple Sclerosis in Controlled Environment.","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Actimyo°;   Device: IMU&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Dr. Stéphanie Delstanche;   SYSNAV;   Centre Hospitalier Universitaire de Liège&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-17T16:00:00Z","discovery_date":"2021-05-17T17:47:26Z","link":"https://clinicaltrials.gov/ct2/show/NCT04888689?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":76,"title":"The Effects of Respiratory-based Telerehabilitaion in Patients With MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Telerehabilitation;   Compliance, Patient&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: pulmonory based home exercises&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Dr. Anıl Tosun;   Trakya University&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","published_date":"2021-05-14T16:00:00Z","discovery_date":"2021-05-14T12:06:26Z","link":"https://clinicaltrials.gov/ct2/show/NCT04887051?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":75,"title":"Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab (KYRIOS)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ofatumumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-03T16:00:00Z","discovery_date":"2021-05-13T16:26:30Z","link":"https://clinicaltrials.gov/ct2/show/NCT04869358?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":74,"title":"An Examination of Cognitive Fatigue Using Functional Neuroimaging","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Zeposia&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Kessler Foundation;   Celgene;   Hackensack Meridian Health;   St. Barnabas Medical Center&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-13T16:00:00Z","discovery_date":"2021-05-13T10:18:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04885894?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":73,"title":"Holter of Movement in Patients With Multiple Sclerosis in Uncontrolled Environment.","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: Actimyo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Dr. Stéphanie Delstanche;   SYSNAV;   Centre Hospitalier Universitaire de Liège&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-12T16:00:00Z","discovery_date":"2021-05-12T10:42:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04882891?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":72,"title":"Sport, Rehabilitation and Nutrition in Multiple Sclerosis: The LINUS Project","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: B-HIPE (Brief High Impact Preparatory Experience)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Fondazione Don Carlo Gnocchi Onlus&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-11T16:00:00Z","discovery_date":"2021-05-11T11:06:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04881422?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":70,"title":"Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: SAR441344 IV;   Drug: placebo IV;   Drug: SAR441344 SC;   Drug: placebo SC;   Drug: MRI contrast-enhancing preparations&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sanofi&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-10T16:00:00Z","discovery_date":"2021-05-10T12:29:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04879628?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":71,"title":"Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Fatigue&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Harvard Medical School;   Gilead Sciences&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-10T16:00:00Z","discovery_date":"2021-05-10T12:29:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04880577?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":69,"title":"Ocrelizuamb for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Radiologically Isolated Syndrome;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ocrelizumab;   Other: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Yale University;   Genentech, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-07T16:00:00Z","discovery_date":"2021-05-07T11:43:30Z","link":"https://clinicaltrials.gov/ct2/show/NCT04877457?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":68,"title":"A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis (RMS)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ofatumumab;   Biological: mRNA COVID-19 vaccine;   Drug: interferon or glatiramer acetate&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-07T16:00:00Z","discovery_date":"2021-05-07T11:43:30Z","link":"https://clinicaltrials.gov/ct2/show/NCT04878211?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":67,"title":"Sonification Techniques for Gait Training","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Parkinson Disease;   Stroke;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Gait rehabilitation with &quot;sonification&quot;;   Other: Standard gait rehabilitation (without sonification)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Istituti Clinici Scientifici Maugeri SpA&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-06T16:00:00Z","discovery_date":"2021-05-06T11:08:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04876339?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":66,"title":"EMDR for Depressed People With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Depression&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Eye Movement Desensitization and Reprocessing - EMDR&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Fondazione Don Carlo Gnocchi Onlus;   EMDR Europe;   Catholic University of the Sacred Heart&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-06T16:00:00Z","discovery_date":"2021-05-06T11:08:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04875832?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":64,"title":"Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With Suppressive Capacity in MS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Dr Recai Turkoglu;   Health Sciences University Istanbul Haydarpaşa Numune Training and Research Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-05T16:00:00Z","discovery_date":"2021-05-05T10:42:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT04874597?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":65,"title":"Sensor-based Assessment and Rehabilitation of Balance in Neurological Diseases","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Stroke;   Multiple Sclerosis;   Parkinson Disease&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Experimental Group;   Other: Control Group&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    IRCCS San Camillo, Venezia, Italy;   IRCCS San Raffaele;   Istituti Clinici Scientifici Maugeri SpA;   IRCCS National Neurological Institute &quot;C. Mondino&quot; Foundation;   I.R.C.C.S. Fondazione Santa Lucia&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-05T16:00:00Z","discovery_date":"2021-05-05T10:42:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT04874051?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":63,"title":"From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Biological sample collection&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Nantes University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-05T16:00:00Z","discovery_date":"2021-05-05T10:42:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT04873492?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":62,"title":"Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ofatumumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-05-03T16:00:00Z","discovery_date":"2021-05-03T11:30:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT04869358?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":61,"title":"Validation of a Novel Instrument Task for Assessing Upper Limb","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Assessment of Arm and Hand Sensorimotor Functions in Multiple Sclerosis Subjects&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Assessment of the upper limb (VPIT + PPIT)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Swiss Federal Institute of Technology;   Kliniken Valens&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-30T16:00:00Z","discovery_date":"2021-04-30T10:48:20Z","link":"https://clinicaltrials.gov/ct2/show/NCT04868370?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":59,"title":"COVID-19 and Multiple Sclerosis Disease Modifying Therapies","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Covid19;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Nottingham University Hospitals NHS Trust&lt;br&#x2F;&gt;&lt;b&gt;Enrolling by invitation&lt;&#x2F;b&gt;","published_date":"2021-04-28T16:00:00Z","discovery_date":"2021-04-28T12:01:02Z","link":"https://clinicaltrials.gov/ct2/show/NCT04863586?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":58,"title":"Validation of the French Adaptation of the MSWDQ-23 Questionnaire","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: questionnaires&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Centre Hospitalier Universitaire de Nice&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-27T16:00:00Z","discovery_date":"2021-04-27T12:25:02Z","link":"https://clinicaltrials.gov/ct2/show/NCT04860791?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":57,"title":"Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Diagnostic Test: Brain MRI;   Diagnostic Test: Spinal Cord MRI;   Diagnostic Test: Retinal imaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Centre Hospitalier Universitaire de Nīmes;   Institut de Recherches en Biothérapie&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-27T16:00:00Z","discovery_date":"2021-04-27T12:25:02Z","link":"https://clinicaltrials.gov/ct2/show/NCT04860947?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":56,"title":"MS Relapses During COVID-19 Pandemic","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Covid19;   Relapsing Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: No Intervention&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Nottingham University Hospitals NHS Trust&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-26T16:00:00Z","discovery_date":"2021-04-26T12:49:02Z","link":"https://clinicaltrials.gov/ct2/show/NCT04858763?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":55,"title":"Effect of Variance on Error Correction During Coupling","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: synchronisation abilities&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hasselt University;   National MS Center Melsbroek;   Noorderhart Revalidatie &amp; MS&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-23T16:00:00Z","discovery_date":"2021-04-23T20:54:01Z","link":"https://clinicaltrials.gov/ct2/show/NCT04856384?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":54,"title":"Running Title: Walking to Music and in Silence on a Treadmill","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Walking with music with synchronisation;   Other: Walking with music without synchronisation;   Other: walking without music&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Hasselt University;   Noorderhart Revalidatie &amp; MS&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-23T16:00:00Z","discovery_date":"2021-04-23T20:54:01Z","link":"https://clinicaltrials.gov/ct2/show/NCT04856345?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":53,"title":"Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapse Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Thomas Jefferson University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-23T16:00:00Z","discovery_date":"2021-04-23T20:54:01Z","link":"https://clinicaltrials.gov/ct2/show/NCT04857489?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":52,"title":"Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Gait Disorders, Neurologic;   Motility Disorder;   Cognitive Impairment&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Robotic Exoskeleton Rehabilitation;   Other: Conventional Gait Therapy&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Kessler Foundation;   Kessler Institute for Rehabilitation&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-22T16:00:00Z","discovery_date":"2021-04-22T20:19:01Z","link":"https://clinicaltrials.gov/ct2/show/NCT04855825?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":51,"title":"Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    NYU Langone Health;   Genentech, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-22T16:00:00Z","discovery_date":"2021-04-22T20:19:01Z","link":"https://clinicaltrials.gov/ct2/show/NCT04855617?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":50,"title":"Investigation of the Effects of Selective Exercise Training in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Exercise&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sanko University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-04-21T16:00:00Z","discovery_date":"2021-04-21T10:57:40Z","link":"https://clinicaltrials.gov/ct2/show/NCT04853654?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":48,"title":"A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Ofatumumab;   Other: Covid-19 vaccine&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-19T16:00:00Z","discovery_date":"2021-04-19T11:50:37Z","link":"https://clinicaltrials.gov/ct2/show/NCT04847596?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":49,"title":"GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Spinal Cord Injuries;   Multiple Sclerosis;   Parkinsonian Disorders;   Allodynia&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: GentleCath™ Air catheter&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    ConvaTec Inc.;   ClinSearch&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-19T16:00:00Z","discovery_date":"2021-04-19T11:50:37Z","link":"https://clinicaltrials.gov/ct2/show/NCT04847609?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":47,"title":"Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Autoimmune or Autoinflammatory Diseases;   HIV;   Multiple Sclerosis;   Solid Tumors or Cancers;   Solid Organ Transplant&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Assistance Publique - Hôpitaux de Paris&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-14T16:00:00Z","discovery_date":"2021-04-14T10:53:38Z","link":"https://clinicaltrials.gov/ct2/show/NCT04844489?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":46,"title":"Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Dietary Supplement: Lutein;   Dietary Supplement: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Illinois at Urbana-Champaign;   Division of Nutritional Sciences, University of Illinois at Urbana-Champaign&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-14T16:00:00Z","discovery_date":"2021-04-14T10:53:38Z","link":"https://clinicaltrials.gov/ct2/show/NCT04843813?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":45,"title":"Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: SARS-COV-2 mRNA Vaccine&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    NYU Langone Health&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-14T16:00:00Z","discovery_date":"2021-04-14T10:53:38Z","link":"https://clinicaltrials.gov/ct2/show/NCT04843774?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":44,"title":"The Effect of Telerehabilitation Based Pilates Training in Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Telerehabilitation-based Pilates Exercise&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Gazi University&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-09T16:00:00Z","discovery_date":"2021-04-09T13:11:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04838886?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":43,"title":"TELEMS: Feasibility of Remote Patient Visits in MS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: EDSS;   Other: Discussion of symptoms&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Medical University of Vienna&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-09T16:00:00Z","discovery_date":"2021-04-09T13:11:11Z","link":"https://clinicaltrials.gov/ct2/show/NCT04838990?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":42,"title":"Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System;   Nervous System Diseases;   Demyelinating Diseases;   Autoimmune Diseases;   Immune System Diseases;   Pathologic Processes&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Dragonfly Research, LLC&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-08T16:00:00Z","discovery_date":"2021-04-08T11:57:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04837651?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":41,"title":"Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University Hospital, Strasbourg, France&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-08T16:00:00Z","discovery_date":"2021-04-08T11:57:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04838015?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":40,"title":"Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Covid19&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    St. Barnabas Medical Center&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-07T16:00:00Z","discovery_date":"2021-04-08T11:57:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04834401?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":39,"title":"Impact of Neuropsychological Disorders in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Three dimensional gait analysis with eyetracking&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-08T16:00:00Z","discovery_date":"2021-04-08T11:57:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04837365?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":38,"title":"Therapeutic Adherence of Multiple Sclerosis Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Study of the role of sociocognitive factors&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-08T16:00:00Z","discovery_date":"2021-04-08T11:57:29Z","link":"https://clinicaltrials.gov/ct2/show/NCT04837352?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":37,"title":"The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Pain, Chronic;   Fatigue Syndrome, Chronic;   Kinesiophobia&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: PMR: Progressive Muscle Relaxation;   Behavioral: BRT:Benson Relaxation Technique&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hacettepe University&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-04-06T16:00:00Z","discovery_date":"2021-04-06T11:14:24Z","link":"https://clinicaltrials.gov/ct2/show/NCT04833673?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":36,"title":"Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Relapsing Remitting Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Natalizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Biogen&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-05T16:00:00Z","discovery_date":"2021-04-05T11:38:24Z","link":"https://clinicaltrials.gov/ct2/show/NCT04832399?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":35,"title":"Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Exposure to methylprednisolone during pregnancy&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Jena University Hospital;   Ruhr University of Bochum;   Interdisciplinary Center of Clinical Research of the Medical Faculty Jena;   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-04-05T16:00:00Z","discovery_date":"2021-04-05T11:38:24Z","link":"https://clinicaltrials.gov/ct2/show/NCT04832269?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":34,"title":"Imaging Evaluation of Central Nervous Autoimmune Diseases","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    MS (Multiple Sclerosis);   NMO Spectrum Disorder&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: MRI&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Qilu Hospital of Shandong University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-30T16:00:00Z","discovery_date":"2021-03-30T11:05:24Z","link":"https://clinicaltrials.gov/ct2/show/NCT04822623?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":33,"title":"Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Biological: Mesenchymal Stem Cells (MSC)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Hadassah Medical Organization&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-03-30T16:00:00Z","discovery_date":"2021-03-30T11:05:24Z","link":"https://clinicaltrials.gov/ct2/show/NCT04823000?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":32,"title":"Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Procedure: SC MRI;   Other: patient questionnaire&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Basel, Switzerland;   Freie Akademische Gesellschaft Basel&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-29T16:00:00Z","discovery_date":"2021-03-29T11:19:37Z","link":"https://clinicaltrials.gov/ct2/show/NCT04819737?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":31,"title":"Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: biological collection&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University Hospital, Rouen&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-29T16:00:00Z","discovery_date":"2021-03-29T11:19:36Z","link":"https://clinicaltrials.gov/ct2/show/NCT04821596?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":30,"title":"Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Urinary Bladder, Neurogenic;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: VESIcare 10Mg Tablet;   Drug: Botox 100 UNT Injection&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Brigitte Schürch;   Centre Hospitalier Universitaire Vaudois&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-26T16:00:00Z","discovery_date":"2021-03-26T13:30:35Z","link":"https://clinicaltrials.gov/ct2/show/NCT04819360?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":29,"title":"The Use of Arabic Otago Exercise Program in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Otago Exercise Program&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Jordan&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-26T16:00:00Z","discovery_date":"2021-03-26T13:30:35Z","link":"https://clinicaltrials.gov/ct2/show/NCT04818008?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":28,"title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Spasticity;   Cerebrovascular Accident;   Multiple Sclerosis;   Traumatic Brain Injury;   Cervical Spinal Cord Injury;   Cerebral Palsy&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: rimabotulinumtoxinB;   Drug: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Supernus Pharmaceuticals, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-25T16:00:00Z","discovery_date":"2021-03-25T11:16:53Z","link":"https://clinicaltrials.gov/ct2/show/NCT04815967?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":27,"title":"Neuroplasticity of Cortical Areas Induced by Cognitive Training in Patients With Multiple Sclerosis MS-NEUROPLAST","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Cognitive Decline&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Cognitive Training&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Aristotle University Of Thessaloniki;   King Fahad Medical City&lt;br&#x2F;&gt;&lt;b&gt;Active, not recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-19T16:00:00Z","discovery_date":"2021-03-19T11:55:20Z","link":"https://clinicaltrials.gov/ct2/show/NCT04806568?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":26,"title":"Virtual Reality in Physical Therapy in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Device: Neuroproprioceptive &quot;facilitation and inhibition&quot; in virtual reality;   Other: Neuroproprioceptive &quot;facilitation and inhibition&quot;&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Charles University, Czech Republic&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-19T16:00:00Z","discovery_date":"2021-03-19T11:55:20Z","link":"https://clinicaltrials.gov/ct2/show/NCT04807738?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":25,"title":"Nature of the Link Between Executive Functions and Theory of Mind in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Theory of Mind&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-19T16:00:00Z","discovery_date":"2021-03-19T11:55:20Z","link":"https://clinicaltrials.gov/ct2/show/NCT04806217?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":24,"title":"Emotions in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Carrying out a tests and questionnaires battery&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Lille Catholic University&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-18T16:00:00Z","discovery_date":"2021-03-18T11:23:53Z","link":"https://clinicaltrials.gov/ct2/show/NCT04804787?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":23,"title":"Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Clinically Isolated Syndrome&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: blood sample;   Biological: cerebro-spinal fluid&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University Hospital, Bordeaux;   University of Bordeaux&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-15T16:00:00Z","discovery_date":"2021-03-15T14:45:21Z","link":"https://clinicaltrials.gov/ct2/show/NCT04798651?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":22,"title":"Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Providence Health &amp; Services&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-15T16:00:00Z","discovery_date":"2021-03-15T14:45:21Z","link":"https://clinicaltrials.gov/ct2/show/NCT04796584?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":21,"title":"Role of Individualized Versus Traditional Exercise in Combating Fatigue","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Other: Adapted and individualized physical training program;   Other: traditional training program&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Centre Hospitalier Universitaire de Saint Etienne&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-12T17:00:00Z","discovery_date":"2021-03-12T14:58:20Z","link":"https://clinicaltrials.gov/ct2/show/NCT04796272?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":19,"title":"3D FLAIR Versus Coronal T2-WI MRI in Detecting Optic Neuritis (FLACON)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Optic Neuritis;   Multiple Sclerosis;   Encephalopathy&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Magnetic Resonance Imaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Fondation Ophtalmologique Adolphe de Rothschild&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-03-11T17:00:00Z","discovery_date":"2021-03-11T12:25:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04792866?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":20,"title":"Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Optic Neuritis;   Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Diagnostic Test: Magnetic Resonance Imaging&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Fondation Ophtalmologique Adolphe de Rothschild&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-03-11T17:00:00Z","discovery_date":"2021-03-11T12:25:31Z","link":"https://clinicaltrials.gov/ct2/show/NCT04793087?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":18,"title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Secondary Progressive Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: BAF312;   Drug: Baseline disease modifying therapies (DMTs)&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-11T17:00:00Z","discovery_date":"2021-03-11T12:25:30Z","link":"https://clinicaltrials.gov/ct2/show/NCT04792567?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":17,"title":"Open Label Randomized Multicenter to Assess Efficacy &amp; Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Ofatumumab;   Drug: First line DMT&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Novartis Pharmaceuticals&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-09T17:00:00Z","discovery_date":"2021-03-09T14:59:53Z","link":"https://clinicaltrials.gov/ct2/show/NCT04788615?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":16,"title":"T Cell Profiling in Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: Blood Sample&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Boston Children&#39;s Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-09T17:00:00Z","discovery_date":"2021-03-09T14:59:53Z","link":"https://clinicaltrials.gov/ct2/show/NCT04789551?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":12,"title":"ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Pediatric Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Physical Activity (PA) Intervention;   Behavioral: Waitlist attention-control&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    The Hospital for Sick Children;   Children&#39;s Hospital of Philadelphia;   University of Alabama at Birmingham;   Queen&#39;s University;   National Multiple Sclerosis Society&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-04T17:00:00Z","discovery_date":"2021-03-08T13:43:03Z","link":"https://clinicaltrials.gov/ct2/show/NCT04782466?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":15,"title":"Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis, Relapsing-Remitting;   Sexual Dysfunction&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Behavioral: Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Alabama at Birmingham;   National Multiple Sclerosis Society&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-02-24T17:00:00Z","discovery_date":"2021-03-08T13:43:03Z","link":"https://clinicaltrials.gov/ct2/show/NCT04768777?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":14,"title":"miRNA Biomarkers in Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   miRNA;   Epigenetic;   Biomarker&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Genetic: miRNA&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    University of Gaziantep&lt;br&#x2F;&gt;&lt;b&gt;Completed&lt;&#x2F;b&gt;","published_date":"2021-02-26T17:00:00Z","discovery_date":"2021-03-08T13:43:03Z","link":"https://clinicaltrials.gov/ct2/show/NCT04772495?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":13,"title":"Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis (MS)&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Other: At-home natalizumab treated MS patient&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Nantes University Hospital;   Rennes University Hospital&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-02T17:00:00Z","discovery_date":"2021-03-08T13:43:03Z","link":"https://clinicaltrials.gov/ct2/show/NCT04777539?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":11,"title":"Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    &lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Medical Valley Digital Health Application Center GmbH;   Celgene Corporation;   NeuroSys GmbH;   Fraunhofer Institute for Integrated Circuits IIS;   Portabiles HealthCare Technologies GmbH;   University of Regensburg&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-02-25T17:00:00Z","discovery_date":"2021-03-08T13:43:03Z","link":"https://clinicaltrials.gov/ct2/show/NCT04771858?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":10,"title":"Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple Sclerosis","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    Multiple Sclerosis;   Pathologic Processes;   Sclerosis;   Autoimmune Diseases of the Nervous System;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Behavioral: Standard Exercise Training;   Device: Phoenix Exoskeleton suit&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Sheffield Teaching Hospitals NHS Foundation Trust&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-08T17:00:00Z","discovery_date":"2021-03-08T13:43:03Z","link":"https://clinicaltrials.gov/ct2/show/NCT04786821?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":9,"title":"Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Drug: Belimumab;   Drug: Short-course Ocrelizumab;   Drug: Continued Ocrelizumab&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Johns Hopkins University;   GlaxoSmithKline&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-02-23T17:00:00Z","discovery_date":"2021-03-08T13:43:03Z","link":"https://clinicaltrials.gov/ct2/show/NCT04767698?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":8,"title":"The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Dietary Supplement: High Phenolic Extra Virgin Olive Oil&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    University of Cyprus;   World Olive Center for Health;   Ellis-Farm, Eliama Daily Value&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-08T17:00:00Z","discovery_date":"2021-03-08T13:43:03Z","link":"https://clinicaltrials.gov/ct2/show/NCT04787497?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":6,"title":"Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Mavenclad®&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-01T17:00:00Z","discovery_date":"2021-03-08T12:17:02Z","link":"https://clinicaltrials.gov/ct2/show/NCT04776213?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":7,"title":"Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Multiple Sclerosis&lt;br&#x2F;&gt;&lt;b&gt;Intervention&lt;&#x2F;b&gt;:    Drug: Mavenclad®&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-05T17:00:00Z","discovery_date":"2021-03-08T12:17:02Z","link":"https://clinicaltrials.gov/ct2/show/NCT04783935?cond&#x3D;Multiple+Sclerosis&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":5,"title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations (SARS)","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    SARS-CoV Infection;   COVID-19;   Allergic Reaction;   Mast Cell Disorder;   Non-atopic&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Moderna COVID-19 Vaccine;   Biological: Pfizer-BioNTech COVID-19 Vaccine;   Biological: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN);   Rho Federal Systems Division, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-02-21T17:00:00Z","discovery_date":"2021-03-02T14:12:09Z","link":"https://clinicaltrials.gov/ct2/show/NCT04761822?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":1,"title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    SARS-CoV Infection;   COVID-19;   Allergic Reaction;   Mast Cell Disorder;   Non-atopic&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: Moderna COVID-19 Vaccine;   Biological: Pfizer-BioNTech COVID-19 Vaccine;   Biological: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN);   Rho Federal Systems Division, Inc.&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-02-21T17:00:00Z","discovery_date":"2021-02-27T01:00:00Z","link":"https://clinicaltrials.gov/ct2/show/NCT04761822?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":3,"title":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","summary":"&lt;b&gt;Conditions&lt;&#x2F;b&gt;:    SARS-CoV-2 Infection;   COVID-19;   Maternal Immunization&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: BNT162b2;   Other: Placebo&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    BioNTech SE;   Pfizer&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-02-15T17:00:00Z","discovery_date":"2021-02-27T01:00:00Z","link":"https://clinicaltrials.gov/ct2/show/NCT04754594?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":2,"title":"National Cohort Study of Effectiveness and Safety of SARS-CoV-2&#x2F;COVID-19 Vaccines (ENFORCE)","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    SARS-CoV Infection&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: COMIRNATY - BioNTech Manufacturing GmbH;   Biological: COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH;   Biological: COVID-19 Vaccine AstraZeneca suspension for injection&lt;br&#x2F;&gt;&lt;b&gt;Sponsors&lt;&#x2F;b&gt;:    Jens D Lundgren, MD;   Ministry of the Interior and Health, Denmark&lt;br&#x2F;&gt;&lt;b&gt;Recruiting&lt;&#x2F;b&gt;","published_date":"2021-02-18T17:00:00Z","discovery_date":"2021-02-27T01:00:00Z","link":"https://clinicaltrials.gov/ct2/show/NCT04760132?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null},{"trial_id":4,"title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","summary":"&lt;b&gt;Condition&lt;&#x2F;b&gt;:    Chronic Liver Disease&lt;br&#x2F;&gt;&lt;b&gt;Interventions&lt;&#x2F;b&gt;:    Biological: BNT162b2;   Biological: CoronaVac;   Biological: AZD1222&lt;br&#x2F;&gt;&lt;b&gt;Sponsor&lt;&#x2F;b&gt;:    Humanity &amp; Health Medical Group Limited&lt;br&#x2F;&gt;&lt;b&gt;Not yet recruiting&lt;&#x2F;b&gt;","published_date":"2021-03-01T17:00:00Z","discovery_date":"2021-01-03T01:00:00Z","link":"https://clinicaltrials.gov/ct2/show/NCT04775069?term&#x3D;biontech&amp;amp;sfpd_d&#x3D;14&amp;amp;sel_rss&#x3D;new14","source":"Clinical Trials.gov","relevant":null}]